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Abstract 
 
Exon skipping using antisense oligonucleotides (AONs) has successfully been used to 
reframe the mRNA in various DMD (Duchenne muscular dystrophy) patients carrying 
deletions and in the mdx mouse model. This study can be devided in two parts: in the 
first part we have tested the feasibility of the exon skipping approach for patients with 
small mutations in in-frame exons, while in the second part a quantitative comparison of 
exon skipping revealing techniques is addressed. 
We first identified 55 novel disease-causing point mutations. We selected 5 patients 
with nonsense or frameshifting mutations in exons 10, 16, 26, 33 and 34. Wild type and 
mutation specific 2‟OMePS AONs were tested in cell-free splicing assays and in 
cultured cells derived from the selected patients. The results obtained confirm cell-free 
splicing assay as an alternative system to test exon skipping propensity when patients‟ 
cells are unavailable. In myogenic cells, similar levels of exon skipping were observed 
for wild type and mutation specific AONs for exons 16, 26 and 33, while for exon 10 and 
exon 34 the efficiency of the AONs was significantly different. Interestingly, in some 
cases skipping efficiencies for mutated exons were quite dissimilar compared to what 
previously reported for the respective wild type exons. This behaviour may be related to 
effect of the mutations on exon skipping propensity and highlights the complexity of 
identifying optimal AONs for skipping exons with small mutations. 
In the second part we compared different techniques to reveal the exon skipping levels 
in the muscles of 7 different mdx mice. An absolute quantification of the dystrophin 
transcript amount was possible using a digital array. Results underline the low 
expression of the dytrophin gene and the amount needed to correctly quantify the exon 
skipping percentage. 
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1. Phenotype 
 
Duchenne muscular dystrophy (DMD) is a severe, progressive, muscle-wasting 
neuromuscular disorder (Emery 2002). The worldwide incidence of DMD is estimated to 
be 1 in 3500 newborn boys (Moser 1984). The first symptoms involve the lower limbs 
and appear between the third and fifth year. Patients have hypertrophic calves, show 
difficulty in running and climbing stairs, run on their tiptoes and frequently fall. Due to 
weakness of the knee and hip extensors, patients rise from a sitting position using the 
Gower's maneuver (patients rest on their hands and toes, and then use their hands to 
push down on their thighs to get into an upright position). Muscle weakness progresses 
to the shoulder girdle-, upper armand trunk-muscles and patients loose ambulance 
before the age of 12 (a detailed description of the clinical features can be found in 
(Emery 1993)). 
Histological changes are readily apparent with light microscopy analysis of cross-
sections from patient muscle biopsies (Figure 1). They involve variation in fiber size with 
atrophic and hypertrophic fibers, degeneration and regeneration of the muscle fibers, 
infiltration of inflammatory cells and fibrosis (Dubowitz 2000). The fiber necrosis results 
in leakage of the enzyme creatine kinase (CK), resulting in very high serum CK levels in 
DMD patients (20,000 to 50,000 U/L compared to 80 to 250 U/L in unaffected 
individuals). These levels decline as patients get older and the overall muscle mass  
decreases progressively. 
Until the early nineties of the last century, patients used to die from respiratory 
insufficiency in the second decade of their life. Nowadays, patients live into their third 
decade, due to improved respiratory care and assisted ventilation, and often die as a 
result of congestive cardio-myopathy (Emery 2002; Simonds 1998). A substantial 
proportion, however, still dies before their twenties from pneumonia or other respiratory 
infections.  
One third of all affected boys are also mentally impaired. About 20% of DMD patients 
have an IQ of less than 70 (Emery 2002) and learning difficulties are commonly 
associated with the disease (Polakoff 1998). In contrast to the muscle wasting, the 
mental impairment is not progressive. 
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2. Positionl cloning of the DMD gene 
Since in general only boys are affected by DMD, it was obvious to geneticists that the 
gene mutated in DMD patients, had to be located on the X-chromosome. A few, rare, 
cases of female DMD patients have been described. In the majority of these females, 
the disease was associated with translocations in the Xp21 band, indicating that the 
DMD locus was located in this region (Greenstein 1977; Jacobs 1981). Besides this 
cytogenetical evidence, genetic linkage analysis also localized the DMD locus to the 
Xp21 band (Davies 1983). Using probes located in and around this band prenatal 
diagnosis and carrier detection was performed as early as 1985 (Bakker 1985). 
Surprisingly, linkage analysis localized Becker muscular dystrophy (BMD) to the same 
locus as DMD (Kingston 1984). BMD affects 1 in 20,000 men, and patients also suffer 
from muscle weakness. However, the course of the disease is more benign than for 
DMD (Emery 2002). Patients have a phenotype that varies from very mild to moderately 
severe. The age of onset is around 12 years, but some patients remain asymptomatic 
until later in life. Most patients lose ambulance around 20-30 years after diagnosis 
(Emery 1993), although some remain ambulant for much longer (England 1990; 
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Mirabella 1998; Yazaki 1999). About 50% of all BMD patients suffer from 
cardiomyopathy, which sometimes is the main symptom (de Visser 1990; Emery 1993). 
Severely affected patients die between 40 and 50 years, whereas mildly affected 
patients have near normal life expectancies. The pERT87 probe, which is deleted in 
some DMD patients, was shown to be deleted in several BMD patients as well (Hart 
1987), suggesting that DMD and BMD are either allelic or that the genes mutated in 
these diseases are close together. Using different probes the first partial DMD cDNAs 
were identified by Monaco and collegues in 1986 (Monaco 1986), whereupon the 
complete 14 kb DMD cDNA could be cloned in 1987 (Koenig 1987). The gene 
(described in more detail in Chapter 3) was found to contain at least 60 exons and to be 
dispersed over at least 2000 kb. Deletions in the DMD gene were found in 50% of all 
patients using cDNA probes (den Dunnen 1987; Koenig 1987). Following studies found 
similar or even higher percentages of deletions in DMD patients as well as in BMD 
patients (Davies 1988; Den Dunnen 1989; Forrest 1988). The protein product of the 
DMD gene was identified shortly after the DMD cDNA. It was named 'dystrophin', 
because of its identification via the isolation of the Duchenne muscular dystrophy locus 
(Hoffman 1987). The protein was shown to be approximately 400 kD and to represent 
0.002% of total striated muscle protein (Hoffman 1987). Dystrophin could not be 
detected in muscle tissue isolated from DMD patients. Microscopic analysis of cross-
sections revealed that dystrophin is located in the sarcolemma in unaffected muscle 
tissue, and confirmed that it is absent in muscles from DMD patients (Arahata 1988; 
Bonilla 1988; Watkins 1988; Zubrzycka-Gaarn 1988) (Figure 1C-F). In contrast to DMD 
patients, dystrophin could be detected in BMD patients (Figure 1E). Western blot 
analysis revealed that these dystrophins were of an abnormal size, but present in near 
normal levels in mildly affected BMD patients, and in low amounts for more severely 
affected patients (Hoffman 1988). These findings implied that the amount of the protein 
was more important than the size of the protein. In 1988 Monaco and colleagues 
proposed the open reading frame hypothesis, by which the phenotypic differences 
between DMD and BMD patients could be explained (Monaco 1988). This model was 
based on the breakpoints of intragenic DMD deletions and their effect on the translation 
of triplet codons into amino acids of the dystrophin protein. They hypothesized that 
deletions in DMD patients lead to a shift in the open reading frame, resulting in 
premature stop codons and truncated non-functional, instable proteins, associated with 
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the severe DMD phenoptype. In BMD patients the deletions do not disrupt the open 
reading frame and internally deleted, but semi-functional dystrophins can be produced, 
leading to a milder phenotype (See Figure 2 for a schematic depiction). Some studies 
detected mutations that contradicted this 'open reading frame rule', and suggested that 
the location of the mutation determined the outcome of the disease (Malhotra 1988; 
Medori 1989). However, the vast majority of these exceptions consisted of BMD 
patients carrying an out-of-frame deletion of exon 3-7 (discussed in more detail in 
Chapter 6). An extensive study revealed that for mutations detected on DNA level the 
reading frame rule holds true for over 90% of all BMD and DMD patients (Baumbach 
1989; Gillard 1989; Koenig 1989), and this rule is generally used as a differential 
diagnotic and prognostic tool for BMD versus DMD patients.  
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3. The DMD gene 
 
The DMD gene is the largest known gene and consists of no less than 2,2 Mb, making it 
80 times as big as the average human gene (estimated to be 30 kb (Nebert 2002)). The 
gene contributes to approximately 0.1 % of the human genome (Lander 2001). When 
compared to the average gene (spanning ~6 kb and containing ~10 exons (Lewin 
2000)), the DMD mRNA is larger (14 kb) and contains more exons (79) (Roberts 1993). 
However, there are genes that contain even more exons and have larger mRNAs than 
the DMD gene, but which are nevertheless shorter. This can be explained by the fact 
that the coding sequence of the DMD gene accounts for only 0.6% of the gene and the 
rest of the gene is occupied by huge non-coding introns (Ahn 1993) (Figure 3). The 
dystrophin gene is also unusually large in other organisms, such as the mouse (Mus 
musculus; 2.2 Mb where the average murine gene is 27 kb and the pufferfish (Fugu 
rubripes; 165kb vs. 4,8 kb for an average gene); and much larger than the average 
gene in the fruitfly (Drosophila melanogaster; 131 kb vs. 11,3 kb for an average gene). 
 
 
Figure 3. Exons and introns size in the DMD gene. Exons (blue bars) an introns (red bars) are 
indicated. 
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Since the extreme size of the gene makes it very vulnerable for pathological 
rearrangements, the question arises why this gene is so large. One hypothesis is, that it 
prevents the dystrophin protein from being present too early during myogenesis and 
brain formation. Full-length dystrophins are mainly transcribed in post-mitotic cells in 
muscle and brain. During mitosis, there is a decrease in transcription and it would be 
almost impossible to express a gene that takes an estimated 16 hours to transcribe 
(Tennyson 1995) in early embryonic cells that divide every 24 hours. Another 
hypothesis is that the introns contain regulatory elements for (alternative) splicing 
events. This theory is supported by the fact that in-frame exons, which can be skipped 
without serious consequences, are on average flanked by smaller introns than out-of-
frame exons, which will result in the generation of a truncated, non- functional 
dystrophin when abusively skipped (Pozzoli 2003). 
The huge size of the introns requires an enormous effort of the transcription and splicing 
machinery of the cell. Furthermore, the predicted splice sites of the DMD exons are not 
significantly stronger than those of other genes (Sironi 2001), yet the splicing machinery 
manages to correctly splice the 14 kb mRNA from the 2.4 Mb pre-mRNA for the majority 
of the transcripts. This is even more astonishing if you appreciate that for instance intron 
44 is almost 250 kb long, and that exon 2 is flanked by 360 kb of intron sequence (i.e. 
190 kb for intron 1 and 170 kb for intron 2), in which many other potential exons are 
located, with equally good or better splice sites than the exon itself. It may be that the 
genuine exons are recognized due to additional signals present in the introns, or due to 
the secondary structure of the pre-mRNA. 
The dystrophin pre-mRNA is subjected to alternative splicing throughout its coding 
sequence (Sironi 2002). In the C-terminal part the in-frame exon 71 and the out-of-
frame exon 78 are omitted in 50% of dystrophin transcripts (Feener 1989). The absence 
of exon 78 results in an alternative C-terminus, which may have a function in 
development (see Chapter 5). Exons 71-74 code for a syntrophin binding domain and 
the functional meaning of the loss of this site is not yet known. Several transcripts 
lacking up to 17 exons in the 5' part have been described (Surono 1997 and 1999). 
Since most of these skips result in an in-frame mRNA, they are thought to generate 
internally truncated dystrophins that lack the actin-binding domains. The function of 
these proteins is as yet unknown, and it may be that they are unstable and/or non 
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functional. Besides the exclusion of exons, one exon has been described that is 
alternatively inserted into the transcript. Exon 2a is situated in intron 2 and is inserted 
either between exon 2 and 8 or between exon 2 and 18. These transcripts have been 
detected in skeletal muscle, small intestine and colon tissue (Pramono 2000). Exon 2a 
creates a shift in the reading frame. Therefore, the insertion of these exons is more 
likely to be a naturally occurring artefact (i.e. mistake of the splicing machinery) or an 
experimental artefact (i.e. cold-shock effect on splicing) than the genuine insertion of an 
alternative exon. Alternative splicing allows expression of the dystrophins isoforms (see 
Chapter 5) driven by at least 7 promoters. Three are located before exon 2 (the cortical, 
muscle and purkinje promoters), whereas the other four are located in intron 29, 44, 55 
and 62 (Dp260, Dp 140, Dp116 and Dp71/40, respectively) (Byers 1993; Chelly 1990b; 
D'Souza 1995; Gorecki 1992; Lederfein 1992; Lidov 1995) (Figure 4 A).  
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Another mysterious aspect of the DMD gene is the final exon, which is 2307 bp long, 
but only codes for the last 3 amino acids of the dystrophin protein, and the last 31 amino 
acids for the alternatively spliced isoforms that lack exon 78. Several parts of this large 
3' UTR are unusually well-conserved in human, mouse and chicken dystrophin 
(Greener 2002; Lemaire 1988) and a deletion within the 3' UTR has been described in 
one BMD patient (Love 1990) and a DMD patient (Spitali 2009). This implies that the 
UTR may have a regulatory function, although one that as yet remains unknown.  
 
 
4. Dystrophin and the dystrophin associated Glycoprotein Complex (DGC) 
Dystrophin consists of 3685 amino acids and is a 427 kD protein (Koenig 1988). The 
protein is hydrophilic (31% of the amino acids are charged) and does not have stretches 
of hydrophobic amino acids, indicating that it is not a transmembrane protein. 
Dystrophin contains four distinct domains (Figure 4 B). The first 240 N-terminal amino 
acids define the actin-binding domain, which contains two actin-binding sites (Jarrett 
1995; Koenig 1990). This domain is followed by a central rod shaped domain, which 
consists of 24 spectrin-like repeat units interrupted by 4 proline-rich hinge regions 
(Koenig 1990). It has recently been shown that repeat units 11-17 contain an additional 
actin-binding domain (Rybakova 1996). The cysteine-rich domain encompasses amino 
acids 3080 to 3360 and includes 15 cysteines, two EF hand motifs and a ZZ domain 
(Koenig 1988). The C-terminal domain consists of the final 325 amino acids, and 
contains two stretches that are predicted to form α-helical coiled coil domains, which are 
involved in protein-protein interactions (Koenig 1988). Dystrophin is part of the 
dystrophin-associated glycoprotein complex (DGC) (Figure 5). The cysteine-rich and C-
terminal domains of dystrophin bind to several parts of the DGC (Figure 5 A), which can 
be divided into the dystroglycan complex, the sarcoglycan-sarcospan complex and the 
cytoplasmatic, dystrophin containing complex (Blake 2002; Yoshida 1994). In skeletal 
muscle the dystroglycan complex consists of α-dystroglycan and β-dystroglycan, which 
are both heavily glycosylated (Ibraghimov-Beskrovnaya 1992). Dystrophin binds to β-
dystroglycan, a transmembrane protein that binds to the extra-cellular α-dystroglycan. 
Alpha-dystroglycan on its part binds to the extracellular matrix component laminin-2 
(Hohenester 1999; Rentschler 1999; Suzuki 1994). In this way dystrophin provides a 
mechanical link between the actin cytoskeleton and the extra-cellular matrix of the 
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connective tissue. The sarcoglycan-sarcospan complex includes α-, β-, γ- and δ- 
sarcoglycan and sarcospan (Blake 2002). These transmembrane proteins are 
hypothesized to have a function in the stabilisation of the dystroglycan-dystrophin 
complex (Araishi 1999). The cytoplasmatic part of the DGC includes dystrophin itself, α-
dystrobrevin and α-syntrophin. Alpha-dystrobrevin binds to both dystrophin and α-
syntrophin (Ahn 1996). Alpha-syntrophin also binds to dystrophin and, additionally, it 
recruits the enzyme nNOS to the sarcolemma (Ahn 1995; Brenman 1996; Brenman 
1995; Yoshida 1995). 
 
 
 
 
In DMD patients the absence of dystrophin results in the complete loss or decrease of 
other DGC proteins, and in the loss of nNOS at the sarcolemma (Brenman 1995; 
Ervasti 1990; Ohlendieck 1991a). 
In BMD patients, on the other hand, the internally truncated dystrophins are able to bind 
to the dystrophin associated proteins, since the C-terminal part of the protein is intact. 
For most BMD patients the DGC proteins can be detected at the membrane, although in 
some cases at decreased levels (Matsumura 1994a; Matsumura 1993; Mirabella 1998). 
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The function of the DGC is still largely unknown. However, since the complex forms a 
mechanical link between the cytoskeleton and the extracellular matrix, it is assumed 
that the DGC has a function in maintaining sarcolemma stability during contraction 
(Matsumura 1994b). Recent studies suggest that the DGC may also have a function in 
signal transduction, because some DGC proteins can bind to proteins, which are 
involved in signalling transduction, such as calmodulin, Grb2 and nNOS (reviewed in 
(Blake 2002; Rando 2001)). Additionally the DGC seems to be required for the 
functionality of the blood brain barrier, as its permeability is increased and its integrity is  
lost in mdx mice (the mouse homologue of DMD, see Chapter 8) (Nico 2003; Nico 2004; 
Vajda 2002). The loss of blood brain barrier function may underlie the mental 
retardation observed in a portion of DMD patients. The loss of other DGC proteins can 
also result in muscular dystrophies. Mutations in the α-sarcoglycan gene found in Limb-
girdle muscular dystrophy type 2D (LGMD) and in severe childhood autosomal 
recessive muscular dystrophy (SCARMD) patients (Piccolo 1995; Roberds 1994).  
Mutations in the other sarcoglycan genes are found in patients suffering from other 
types of LGMD (Bonnemann 1995; Lim 1995; Nigro 1996; Noguchi 1995). As yet no 
mutations in the sarcospan or syntrophin genes have been found in patients suffering 
from muscular dystrophy or other diseases. Moreover, transgenic sarcospan and 
syntrophin knockout mice do not develop a muscular dystrophy phenotype (Kameya 
1999; Lebakken 2000). Dystroglycan knockout mice, on the other hand, are embryonic 
lethal (Williamson 1997). Recently, mutations in genes coding for fukutin and fukutin 
related protein have been identified in congenital muscular dystrophy (CMD) and 
LMGD-2I patients (Brockington 2001b; Kobayashi 1998). These proteins are thought to 
be glycosyl-transferases, and are likely to be involved in the glycosylation of α-
dystroglycan. Indeed, the expression of α-dystroglycan is decreased in CMD and 
LMGC-2I patients (Brockington 2001a; Hayashi 2001). The exact pathophysiology of 
DMD is not yet known, but a hypothetical flowchart describes the most important 
mechanisms thought to give rise to the muscle wasting that is found in DMD patients. 
Due to the lack of dystrophin and the DGC complex in DMD patients, the muscle 
membrane is leaky and more vulnerable for mechanical damage (Blake 2002). This 
results in an influx of calcium into the muscle fiber, leading to a calcium overload of the 
mitochondrial matrix and the down-regulation of the transcription of mitochondrial 
genes, resulting in a metabolic crisis and eventually necrosis (Chen 2000). The calcium 
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influx also over stimulates calcium dependent signal transduction pathways, which 
eventually causes a downregulation of calcium regulating signal molecules through a 
negative feedback, enhancing the metabolic crisis (Chen 2000). Finally, the calcium 
influx activates calcium dependent proteases in general, and the calpaines in particular 
(Alderton 2000; Spencer 1995). The proteases break down the muscle membrane and 
modify calcium leak channels, thus augmenting the influx of calcium into the cell 
(Alderton 2000). Due to the muscle damage the fiber becomes "leaky" and muscle 
enzymes such as creatin kinase will leak into the bloodstream. Additionally, since nNOS 
synthesizes the molecule NO that induces vaso-dilatation, the absence of nNOS can 
cause ischemia after severe mechanical stress. This can lead to necrosis (Sander 2000, 
Thomas, 1998), which attracts inflammatory cells, such as dendritical cells, mast cells 
and T-cells, which eventually trigger fibrosis (McDouall 1990; Nahirney 1997). 
 
 
5. Dystrophin isoforms and homologs 
Besides the dystrophin initially detected in skeletal muscle and cardiomyocytes, at least 
seven promoters drive the expression of other dystrophin isoforms from the DMD gene 
(Figure 4 B, Table 1). In addition to the muscle dystrophin – named Dp427m, because 
of its molecular weight (427 kD) and its main site of expression (muscle) – two other full-
length dystrophins are produced, i.e. Dp427c and Dp427p (Boyce 1991; Chelly 1990b; 
Gorecki 1992; Holder 1996). Both isoforms have their own unique first exon, which is 
spliced to exon two of the Dp427m transcript (Boyce 1991; Gorecki 1992). Dp427c is 
mainly expressed in the cortical neurons – hence the postfix 'c' – and the hippocampus 
in the brain (Barnea 1990; Gorecki 1992), whereas Dp427p is expressed in the 
cerebellar Purkinje cells and at lower levels in skeletal muscle (Gorecki 1992; Holder 
1996). There are also four internal promoters from which shorter isoforms are produced; 
(Byers 1993; D'Souza 1995; Hugnot 1992; Lidov 1995) named after their respective 
molecular weights. Dp260 is expressed in the retina and is derived from a unique first 
exon, located in intron 29, which is spliced to exon 30 of Dp427m (D'Souza 1995). Two 
Dp260 isoforms (Dp260-1 and Dp260-2) are formed by alternative splicing of the first 
exon and a different translation initiation site. Dp260 lacks the N-terminal domain, two 
hinge regions and nine repeats, when compared to the fulllength dystrophins. The 
promoter of Dp140 is located in intron 44 (Lidov 1995). The methionine translation 
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initiation codon, however, is located in exon 51, and as a consequence this protein does 
contain a large 5' untranslated region (UTR), but no isoform specific amino acids. 
Dp140 has retained only the last two hinge regions, five of the spectrin-like repeats, the 
cysteine-rich and C-terminal domain. The protein is found throughout the central 
nervous system (Lidov 1995). Dp116 has a unique N-terminal part, which is coded by 
an exon located in intron 55. This exon is spliced to exon 56 of Dp427m, which codes 
for the distal part of the 21st repeat unit (Byers 1993). This isoform is expressed in 
Schwann cells. Dp71 and Dp40 derive from a unique first exon in intron 62 that is 
spliced to exon 63 (Blake 1992; Feener 1989; Hugnot 1992; Lederfein 1992; Tinsley 
1993). Both proteins have an alternative C-terminal domain when compared to the other 
dystrophin isoforms. In Dp71 exon 78 is often omitted, resulting in a shifted reading 
frame and the insertion of 31 new amino acids instead of the original final 13 amino 
acids (Lederfein 1992). These amino acids are mainly hydrophobic, whereas the 
original C-terminal part is hydrophilic. Dp40 uses an alternative poly adenylation site 
located in intron 70, which results in a shortened C-terminal domain (Feener 1989; 
Tinsley 1993). Both isoforms are ubiquitously expressed in non-muscle cells (Hugnot 
1992; Tinsley 1993). The diversity of dystrophin isoforms is further increased by 
alternative splicing of the 3' part of the gene (Feener 1989) (see Chapter 3). As yet the 
functional significance of the different dystrophins is unknown. It is assumed that the 
full-length isoforms will have a comparable function to Dp427m, i.e. providing a 
mechanical link between the cytoskeleton and the extracellular compartments. Since 
the shorter isoforms do not contain an actin-binding domain, these dystrophins can only 
bind to the DGC proteins and are thought to be involved in the stabilisation and function 
of non-muscle DGC-like protein complexes (Blake 2002). Dp260 is thought to be 
required for normal retina function, since this isoform is expressed mainly in the retina 
and some DMD patients have abnormal electro-retinograms (D'Souza 1995; Pillers 
1993). The hydrophobic Dp71 has been detected in embryonic tissues and in 
developing muscles (Howard 1999; Sarig 1999). It is replaced by the hydrophilic Dp427 
when the muscle cells mature, indicating that it may have a function in development 
(Howard 1999). The dystrophin isoforms may also have a function in signal 
transduction, either by binding to signalling molecules themselves or by recruiting 
proteins that have a function in signalling transduction (reviewed in (Rando 2000)). 
Dp427c, Dp427p, Dp140 and Dp116 are expressed in brain and the central nervous 
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system. As a result of the mutation one or more isoforms may be absent in addition to 
the Dp427m isoform, and cause the mental impairment sometimes found in DMD and 
BMD patients (Byers 1993; Comi 1995; Gorecki 1992; Lidov 1995). In some studies a 
correlation has been found between the absence of Dp140 (due to mutations spanning 
the Dp140 promoter) and the presence of mental abnormalities in DMD and BMD 
patients (Bardoni 2000; Bushby 1995; Felisari 2000). A very recent study shows the 
correlation between the Full Scale Intelligence Quotients (FSIQ) results with the location 
of the dystrophin gene mutation suggesting that the risk of cognitive deficit is a result of 
the cumulative loss of central nervous system (CNS) expressed dystrophin isoforms, 
and that correct classification of isoform involvement results in improved estimates of 
risk (Taylor 2010). 
 
 
 
In addition to the isoforms derived from the DMD gene, there are also three known 
dystrophin homologues, which are derived from other genes: utrophin, dystrophin 
related protein 2 (DRP2) and dystrobrevin. Utrophin (also called dystrophin related 
protein 1 (DRP1)) shares considerable homology with dystrophin along the entire length 
on both DNA and protein level (Tinsley 1992). 
The utrophin gene is located on chromosome 6 and consists of 74 exons dispersed 
over 0.9 Mb (compared to 2.4 Mb for dystrophin) (Pozzoli 2002). The 13 kb mRNA gives 
rise to a 395 kDa protein (Tinsley 1992), which contains an N-terminal actin binding 
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domain, a central rod domain, a cysteine-rich and C-terminal domain (Tinsley 1992). 
When compared to dystrophin, utrophin lacks repeat units 15 and 19 and hinge regions 
1 and 3 (Winder 1995a), and the N-terminal domain of utrophin has a higher affinity for 
actin (Winder 1995b). Utrophin is ubiquitously expressed (hence the name: ubiquitously 
expressed dystrophin-like protein (Blake 1992)). In muscle fibers utrophin is expressed 
in the neuromuscular synapses and the myotendinous junctions, where it participates in 
post-synaptic membrane maintenance and acetylecholine receptor clustering (Nguyen 
1991). In vitro and in vivo studies have shown that utrophin can bind to β-dystroglycan, 
α-dystrobrevin, syntrophin and the sarcoglycans and it is assumed that utrophin forms a 
DGC-like complex (Matsumura 1992; Peters 1998). In developing and regenerating 
muscle, utrophin is upregulated and present along the entire sarcolemma (Pons 1993). 
This is also observed in DMD patients (Galvagni 2002; Karpati 1993; Mizuno 1993; 
Mizuno 1994), suggesting that there is some functional redundancy between dystrophin 
and utrophin (Blake 2002). However, the utrophin overexpression found in DMD 
patients is apparently too low to fully prevent muscle degeneration (upregulation of the 
utrophin gene as a therapeutic strategy for DMD is discussed in Chapter 10). 
The dystrophin related protein 2 (DRP2) shows similarity to Dp116. It has a unique 
proline-rich N-terminal part, followed by two spectrin-like repeats, a cysteine rich domain 
and a C-terminal domain, which are homologous to those of dystrophin (Roberts 1996). 
DRP2 is not expressed in muscle, but is expressed in brain where it is associated with 
the postsynaptic densities and cholinergic neurons (Roberts 2000). The α- and β-
dystrobrevin proteins are derived from two different genes and both show homology to 
the C-terminal part of dystrophin (Blake 1998; Sadoulet-Puccio 1996; Wagner 1993). At 
least five different α-dystrobrevin isoforms are generated through the use of alternative 
promoters and alternative splicing (Blake 1996; Sadoulet-Puccio 1996). These isoforms 
can bind to dystrophin and are located at the neuromuscular junction (Nawrotzki 1998; 
Peters 1998). Beta-dystrobrevin is expressed in non-muscle cells, and is complexed 
with utrophin and Dp71 (Blake 1999; Loh 2000). Dystrobrevins contain a domain that 
can be phosphorylated by tyrosine kinases, and can associate with several proteins 
involved in signalling transduction (Blake 2002).  
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6. Mutations 
The mutation rate for the DMD coding sequence is estimated at 1 x 10-4 genes per 
generation (Blake 2002). This is high compared to an estimated average mutation rate 
of 1 x 10-5 – 10-6 for human genes (Lewin 2000). As a consequence of this relatively 
high mutation rate, one third of all mutations are de novo (Laing 1993), and there is a 
broad variation of different mutations. Intragenic deletions of one or more exons are 
found in ~65% of all patients (Koenig 1989; White 2002), while duplications are found in 
6-8% of all patients (Galvagni 1994; White 2002). Nonsense or frame-shifting mutations 
in the DMD gene lead to Duchenne muscular dystrophy (DMD) (MIM# 310200), by 
contrast, Becker muscular dystrophy (BMD)(MIM# 310376) is caused by in-frame 
mutations that give rise to a smaller but functional protein (Hoffman 1987; Monaco 
1988). The interruption or maintenance of the dystrophin reading frame by the gene 
mutations explains the phenotypic differences observed in approximately 92% of the 
BMD/DMD cases (Aartsma-Rus 2006a; Koenig 1989). The majority of the deletions and 
duplications cluster into two hotspot regions: the minor hotspot spans exons 2-20 and 
the major hotspot region exons 45-53 (Beggs 1990; Liechti-Gallati 1989). The highest 
numbers of breakpoints are found in the extremely large introns 1, 2 and 7 (major 
duplication and minor deletion hotspots) and 44 (major deletion hotspot) (Tuffery-Giraud 
2009; Fokkema 2005). However, if you correct for the length of the introns (i.e. calculate 
the number of breakpoints per kb intron), relatively high numbers of breakpoints are 
located in introns 45 trough 53. There is as yet no explanation for the preferential 
occurrence of breakpoints in these introns. Extensive analysis of 22 breakpoints in 
intron 49 revealed that the breakpoints were evenly spread throughout the intron, and a 
sequence motive near or at the breakpoints could not be identified (Nobile 2002). 
Further research of breakpoints in introns 47 and 48 showed that most breakpoints 
cluster around intronic motifs that could predispose for double-stranded DNA breaks 
(Sironi 2003; Toffolatti 2002). However, these motives are present throughout the gene 
and not only in intron 47 and 48, so there must be another underlying mechanism for 
the predisposition of breakpoints in the two hotspots (Sironi 2003). Another explanation 
is that the breakpoints are in fact evenly spread throughout the gene, but that we 
observe the hot spots due to the fact that only breakpoints occurring in the hot spots 
result in a phenotype. This may hold true for breakpoints in introns 22 through 40. A 
deletion of this region (that contains only in-frame exons) is usually associated with a 
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very mild phenotype. However, even in-frame deletions in the proximal introns can 
result in a DMD phenotype (Flanigan 2009). 
In some cases a mutation detected in affected siblings, cannot be found in the somatic 
cells of their mother, suggesting that the mutation is only present in part of the germ-line 
cells of the mother (Bakker 1987). The estimated frequency of this so-called germ-line 
mosaicism within a family varies between 12 and 20% (Emery 1995). Unexpectedly, it 
has been shown that deletions found in children from germline mosaic carriers involve 
the proximal part of the gene in 79% of all cases, while mutations in the distal part were 
found in only 21% (Passos-Bueno 1992). The reason for this phenomenon is as yet 
unknown. 
For diagnostic purposes the high frequency of deletions clustering in the hotspots is an  
advantage; 98% of all DMD/BMD deletions can be detected using multiplex PCR of only 
8 exons (Beggs 1990; Chamberlain 1988). Southern blot analysis, multiplex amplifiable 
probe hybridisation (MAPH), Multiplex ligation-dependent probe amplification (MLPA), 
high resolution melting curve analysis (MCA) and comparative genomic hybridization 
array (CGH) can be used to detect the precise range of both deletions and duplications 
(Hodgson 1992; White 2002; Janssen 2005; Almomani 2009; Hegde 2008; Saillour 
2008; del Gaudio 2008; Bovolenta 2008). In about one third of the patients small 
deletions and insertions or point mutations are found (Deburgrave 2007). These 
mutations are evenly spread throughout the gene and are therefore harder to find  
(Flanigan 2009). They can be detected by denaturant gradient gel electrophoresis 
(DGGE), single strand conformation polymorphism analysis (SSCA), direct sequencing 
or chemical cleavage of each individual exon, the protein trunction test (PTT), or by 
single-condition amplification/internal primer (SCAIP) (Dolinsky 2002; Flanigan 2003; 
Hofstra 2004; Roest 1993, Kilimann, 1992; Tuffery 1993; Tuffery-Giraud 1999; Spitali 
2009; Flanigan 2009). The majority of the detected mutations results in-frameshifts, 
non-sense codons, the abolishment of splice sites, or the introduction of cryptic splice 
sites (Kilimann 1992; Tuffery-Giraud 1999; Flanigan 2009). DMD causing missense 
mutations account only for 0,18% of all mutations (Flanigan 2009) and were located in 
an actin-binding domain or in the part of the cysteine rich region that binds to β-
dystroglycan (Goldberg 1998; Lenk 1996; Prior 1995; Flanigan 2009). 
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The reading frame rule holds true for over 93% of all BMD and DMD patients (Aartsma-
Rus 2006a), however exception to the rules are found expecially for 5‟ gene deletions 
occurring in BMD patients, a region known to be hotspot for exceptions (Kesari 2008). 
For in-frame mutations the phenotype is also to some extent determined by the location  
and the size of the deletion (Arikawa-Hirasawa 1995; Beggs 1991; Fanin 1996). Huge 
in-frame deletions removing up to 35 exons in the central rod domain have been 
described for relatively mild Becker patients (England 1990; Fanin 1996; Mirabella 
1998). However, larger deletions are always associated with a DMD phenotype, 
suggesting that at least a small part of the rod domain is required for proper dystrophin 
function (Fanin 1996). Deletions removing only the first part of the central rod domain 
have been found in a-symptomatic individuals, in persons with elevated CK levels and 
in patients suffering from muscle cramps upon exercise (Angelini 1994a; Gospe 1989; 
Ishigaki 1996). In-frame deletions in the major hotspot generally cause typical BMD, 
while deletions in the actin-binding domain cause severe BMD (Beggs 1991). Deletions 
removing both the actin-binding domain and part of the central rod domain usually 
cause DMD (Arikawa-Hirasawa 1995; Fanin 1996; Vainzof 1993). This may be 
explained by the fact that a third actin-binding site is present in the central rod domain 
(Rybakova 1996). The removal of the first two actin-binding domains (located in the 
actin-binding domain) may partially be compensated for by this central rod actin-binding 
domain and therefore cause severe BMD, whereas the deletion of all three domains 
results in DMD. Deletions in the C-terminal domain are usually associated with DMD 
(Bies 1992). In addition to the location of the deletion, the amount of dystrophin 
produced in the patients also correlates with the phenotype: the more dystrophin a 
patient produces, the milder the phenotype (Angelini 1994a; Hoffman 1988). No 
dystrophin or up to 3% of normal levels are usually found in DMD patients, whereas 
levels of over 30% of dystrophin (of an abnormal weight) are found in BMD patients 
(Neri 2007). 
Certain in-frame mutations are always associated with a DMD phenotype, whereas a 
number of out-of-frame mutations lead to a BMD phenotype (Fokkema 2005). In-frame 
mutations may be too large to result in a functional dystrophin or they may be located in 
areas of the protein, which are indispensable (see above). However, for a significant 
part of in-frame DMD patients no dystrophin protein can be detected. This may be 
because additional exons are be spliced out as a consequence of the deletion, resulting 
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in out-of-frame transcripts. Alternatively, the in-frame deletion could lead to an unstable 
dystrophin. Out-of-frame mutations on DNA level associated with a BMD phenotype do 
not necessarily have to be inconsistent with the reading frame rule on RNA level. For 
instance, two nonsense mutations in the in-frame exon 29 disrupt a sequence that is 
required for the proper inclusion of this exon (Ginjaar 2000; Franz 2000). As a result, 
exon 29 (and thus the truncating mutation) is not always included in the transcript by the 
splicing machinery. Dystrophin lacking the amino acids coded by exon 29 can be 
detected in these patients, explaining why they have a BMD and not a DMD phenotype. 
Unfortunately, for the majority of all patients mutations are determined on DNA level 
only, and not confirmed on RNA level. Therefore, it is not known whether apparent 
inconsistencies with the reading frame rule are also present on RNA level. There are 
also a number of deletions (detected on DNA level), which are found in both DMD and 
BMD patients. The majority of these mutations start either in intron 3 or in intron 44. 
Exon 44 skipping in patients with a deletion of exon 45 (Prior 1997; Roberts 1991), or a 
duplication of exon 44 (Aartsma-Rus personal communication) has been described, and 
this might explain the discrepancy: high levels of alternative splicing of exon 44 will 
generate in-frame transcripts and internally deleted dystrophins. These will therefore be 
associated with a BMD phenotype, while no or low levels of exon 44 skipping will result 
a DMD phenotype. The levels of alternative splicing are influenced by the different 
splicing regulation patterns of each individual and will additionally be influenced by the 
extent of the deletions and the location of the breakpoints in intron 44. Even though the 
deletions may seem identical on DNA levels, in reality the exact location of the 
breakpoints differs between individuals of different families. However, as yet no intronic 
regulating sequences that influence the inclusion or exclusion of exon 44 have been 
identified. The deletion of exon 3-7 is the most commonly found and most extensively 
investigated deletion that is associated with both phenotypes. Alternative splicing of 
exon 2 would restore the reading frame for these patients and has been described for 
two BMD patients albeit at levels of 1-2% (Chelly 1990a). Despite extensive research 
exon 2 skipping has not been described elsewhere for patients with this deletion 
(Gangopadhyay 1992; Winnard 1993; Winnard 1995). An explanation for this 
phenomenon may be the use of an alternative translation initiation codon (Winnard 
1995). This hypothesis is supported by the fact that there are three in-frame ATG 
codons present in exon 8. Furthermore, the dystrophins detected in these BMD patients 
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where shown to lack the exon 1 and 2 encoded sequence, but did contain the exon 8 
encoded sequence (Winnard 1995). In addition to BMD and DMD, mutations in the 
DMD gene have also been found in X-linked dilated cardiomyopathy (XLDC) patients 
(Muntoni 1993). These patients have no signs of skeletal myopathy but suffer from 
rapidly progressive congestive heart failure (Milasin 1996). Without heart transplantation 
premature death usually occurs within 2 years after diagnosis (often in their twenties).  
Most mutations are present in the first exon of the muscle specific dystrophin isoform 
and completely abolish dystrophin expression in the heart (Ferlini 1999, Neri 2007). In 
skeletal muscle, on the other hand, upregulation of the purkinje and brain isoforms 
rescues the phenotype (Bastianutto 2001). This upregulation is controlled by the 
dystrophin muscle enhancer 1 that is located downstream of the muscle specific first 
exon, and which increases the expression of the Dp427c and Dp427p isoforms 
exclusively in skeletal muscle cells. In-frame deletions involving exon 48 and exon 49-
51 have been detected in less severely affected XLCD patients, and in BMD patients 
(with or without XLDC) (Ferlini 1999 and Ferlini personal communication).  
 
 
7. Revertant Fibres 
Individual dystrophin-positive fibers have been found in DMD patients and in otherwise 
dystrophin-negative mdx mice (see Chapter 8) (Thanh 1995; van Deutekom 2007; 
Rimessi 2009) (Figure 6). These 'revertant fibers' grow in clusters and comprise 1% to 
10% of all fibers. The frequency of these fibers increases with age in both DMD patients 
(Fanin 1995) and mdx mice (Lu 2000), and after mutagene doses of X-rays in mdx mice 
(Hoffman 1990). The revertant dystrophins are located at the membrane and may be 
functional. The correlation between the amount of revertant fibers and the severity of 
the DMD phenotype is still controversial (Fanin 1995; Nicholson 1993; Thanh 1995). 
Revertant dystrophins were shown to lack domains coded by the exons adjacent to 
exons deleted in the DMD patients (Fanin 1995; Thanh 1995). By omitting these exons 
the reading frame was restored, explaining why BMD-like, probably semi-functional 
dystrophins could be produced. Revertant fibers have been studied more extensively in 
mdx mice (Lu 2000). A few isolated dystrophin positive fibers were detected in newborn 
mice and the amount of revertant fibers, the number of fibers per cluster and the length 
of the fibers increased with age (2 weeks to 18 months). Not only was the dystrophin 
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synthesis restored in revertant fibers, dystrophin and the DGC-complex were also 
correctly located at the membrane, providing more evidence that the revertant 
dystrophin is at least partly functional. Different inframe transcripts lacking multiple 
exons were identified in different clusters. In most dystrophins only domains 
immediately surrounding the mutated exon 23 were missing.  
 
 
 
However, dystrophins lacking up to 35 exons were also detected. Potential mechanisms 
responsible for the occurrence of revertant fibers are somatic reversion and alternative 
splicing (Klein 1992; Lu 2000). There are arguments in favour of, and against, both 
mechanisms. Somatic reversion, i.e. the occurrence of secondary, frame-restoring 
mutations in muscle or muscle precursor cells, fits with the clonal nature of the revertant 
fibers, their increase with age and their appearance after exposure to mutagenic doses 
of X-rays. Conversely, mutations are generally proliferation-related events and would be 
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more likely to occur during the many cell divisions in the embryogenesis than in 
differentiated muscles. However, only very low levels of revertant fibers are found in 
newborn mice. Furthermore, in situ hybridisation experiments were not sensitive enough 
to detect deletions on DNA level with a probe for intron 22 in mdx revertants (the probe 
detected 80% positive nuclei in both dystrophin positive and dystrophin negative fibers). 
This means that there is either no deletion present or that the deletion is present in too 
low a number of nuclei to detect a significant difference. This finding, however, does not 
exclude the possibility of a point mutation in a splice site. In fact, it was recently shown 
that the substitution of one base pair in the acceptor splice site of exon 23 induces 
several different alternative splicing patterns that involve 12 or more exons (Bertoni 
2003). The other potential mechanism, alternative splicing, has been described for the 
DMD gene throughout the coding sequence in both patients and unaffected individuals 
(Sironi 2002). Furthermore, in a substantial part of revertant fibers investigated in mdx 
mice, two non-consecutive domains were absent in the revertant dystrophins, located 
around exon 23 and around exon 40-46 (Lu 2000). Intuitively one would think this to be 
more likely the result of two independent alternative splicing events than of two different 
new mutations. It should be noted, however, that deletions of two non-consecutive parts 
of the DMD gene have been reported for DMD patients (Zatz 1998). Finally, one should 
also not overlook the possibility of a combination of the two mechanisms. Mutations 
frequently occur in the mutation hotspot located between exon 45-55 and alternative 
splicing around exon 23 has been observed both in normal and mdx mice (personal 
observation). 
Alternative splicing seems to be at odds with the clonal nature of the fibers. Lu and 
colleagues proposed that the splicing pattern is changed during degeneration and 
regeneration and that a pattern of frame-restoring splicing is preserved by functional 
selection (Lu 2000). The revertant dystrophin would protect the fiber from degeneration 
and the "splicing imprinting" would expand to adjacent fibers, thus explaining the clonal 
nature of revertant clusters. However, this hypothetical mechanism has never been  
demonstrated. 
 
 
 
 
24 
 
8. Animal models 
 
Several animal models carrying mutations in the DMD gene were reported, among 
these the mdx mouse, the double knockout mdx/utrn-/- mice and the golden retriever 
muscular dystrophy (GRMD) dog are used most. 
The mdx mouse is a naturally occurring dystrophin-deficient mutant, which was first 
described in 1984 in a colony of C57BL/10 mice (C57BL/10ScSnJ) (Bulfield 1984) and it 
is now called C57BL/10ScSn-Dmdmdx/J; it is readily available from commercial breeders 
and thus widely used in basic and translational research. It carries a point mutation in 
exon 23 of the mouse dystrophin gene introducing a premature stop codon, which leads 
to the absence of full-length dystrophin. Mdx mice have a slightly shorter life span as 
compared to wildtype controls (Chamberlain 2007). The muscle degeneration in mdx 
mice differs from DMD patients in that it appears in waves and is not a continuum. At 
first, a marked degeneration and regeneration of muscle fibers is observed at a young 
age (2–4 weeks (McGeachie 1993)), which results in an increase in the number of 
newly differentiating myofibers characterized by centralized nuclei and an increased 
heterogeneity in myofiber size. In parallel, necrosis is observed in muscles at this early 
stage (Grounds 2004; Messina 2006) while it decreases again after 60 days (Spencer 
1996). Subsequently, loss of muscle tissue is slow and general muscle weakness in 
cage-reared animals is not evident until later in life (Lefaucheur 1995). Fibrosis in most 
mdx mouse muscles is less pronounced than in DMD patients with the exception of the 
diaphragm muscle (Stedman 1991; Connolly 2001; Rolland 2006). Although absolute 
muscle force of limb muscles remains comparable to unaffected mice, the relative force 
normalized to body weight decreases by approximately 20% and 50% at the age of 8–
10 weeks and 4 months, respectively (Messina 2006; Connolly 2001; Raymackers 
2003). However, others could not confirm this finding (Burdi 2006; Frysse 2004), which 
is probably based on variations in the mice strains (e.g. body weight, cooperation of the 
animals in force measurement assays) and on different experimental procedures. 
Similarly, a reduced force of contraction has also been reported in isolated muscle 
preparations although the lack of standardized conditions makes it again difficult to 
compare the results obtained by different groups (Deconinck 1998; Lynch 2001; Louis 
2004; Laws 2004). These discrepancies clearly show that the availability of 
standardized experimental protocols would be of advantage both to elucidate basic 
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aspects of the pathology and to test emerging therapeutic strategies. Respiratory 
pathology is evident in 16-month-old mice but not in 4-month-old mice, showing a 
worsening of respiratory capacity with age, in line with the increased histological 
damage of respiratory muscles (Gayraud 2007). Abnormal cardiac function is also seen 
in the mdx mouse sharing several characteristics of DMD-associated cardiomyopathy 
(Quinlan 2004). For example, changes in the electrocardiogram (ECG) and 
echocardiogram have been reported in mice that are older than 6 months (Bia 1999; 
Wehling-Henricks 2005; Spurney 2008). This change in cardiac function is paralleled by 
an increase in myocardial fibrosis and the occurrence of foci of myocardial necrosis and 
inflammation (Quinlan 2004; Van Erp 2006; Cohn 2007; Buyse 2009). Mdx mice have 
served as a model for several studies on calcium homeostasis and alterations thereof. 
Basal cytosolic calcium levels were reported to be identical in mdx and wild-type mice 
(De Backer 2002) showing a very robust calcium homeostasis, possibly due to elevated 
expression of the calcium-buffer parvalbumin (Gailly 1993; Sano 1990). Nevertheless, 
[Ca2+] in the subsarcolemmal compartment (Mallouk 2000) and in the sarcoplasmic 
reticulum (Robert 2001) was increased and levels of inositol 1,4,5-triphosphate (IP3) 
and of the IP3 receptor were higher in mouse and human dystrophic cell lines (Liberona 
1998). Muscle pathology in the mdx mouse can be aggravated by forced exercise, a 
method introduced to allow a better evaluation of the efficacy of experimental therapies. 
Several exercise paradigms have been described (Granchelli 2000; Vilquin 1998; 
Hodgetts 2006). Muscle damage of exercised mdx animals is increased as reflected by 
an increased number of muscle fibers with centralized nuclei and increased fibrosis 
(Burdi 2006; De Luca 2005). Plasma creatine kinase levels are further elevated, calcium 
homeostasis is more severely impaired and fore-limb strength is generally reduced 
(Rolland 2006; Burdi 2006; Fraysse 2004; De Luca 2005) while body weight remains 
unchanged. Cardiomyopathy has been described for the exercised mdx mouse 
(Nakamura 2002), however, a systematic analysis of the impact of exercise on cardiac 
pathology is still lacking.  
In an attempt to aggravate the pathology of the mdx model and to study utrophin-based 
gene therapy strategies, utrophin mutant mice (on C57B5/129J background) were 
crossed with C57BL/10 mdx mice to obtain double knock-out mice (Deconinck 1997; 
Grady 1997). Mice lacking both dystrophin and utrophin share many phenotypical 
hallmarks with DMD. The mice have a markedly reduced life span of 4–20 weeks, 
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severe muscle weakness with joint contractures, kyphosis and a pronounced growth 
retardation that starts around weaning. Necrotic fibers and connective tissue are visible 
in the diaphragm already 6 days after birth and centrally nucleated fibers are evident at 
2 weeks. Interestingly, the diaphragm is not more affected than that of the mdx mice, 
suggesting that utrophin does not compensate for the lack of dystrophin in this muscle 
(Deconinck 1997; Grady 1997). The skeletal muscles appear normal at birth but show 
first signs of degeneration/regeneration already after 2 weeks. Although the dystrophic 
pathology is similar to mdx mice at 4–5 weeks of age, it then remains severe in contrast 
to the improvements seen in mdx mice. By 10 weeks of age, fibrosis is evident in tibialis 
anterior muscle. Occasionally, larger necrotic areas are observed in the heart (Grady 
1997). The neuromuscular and the myotendinous junctions in mdx/utr-/- mice show a 
marked reduction in membrane folds, presumably as a result of the lack of utrophin 
(Deconinck 1997; Grady 1997). Therefore, both the disease progression and the 
phenotype of these double mutant mice resemble the progression of muscle dystrophy 
in DMD patients and the interstitial fibrosis of skeletal muscle lends itself to assess the 
efficacy of anti-fibrotic treatments. 
In the golden retriever, the best characterized dog model, the disease results from a 
single base pair change in the 30 consensus splice site of intron 6, leading to skipping 
of exon 7 and alteration of the reading frame in exon 8, which creates a premature stop 
codon (Sharp 1992). Unlike the dystrophin-deficient mdx mouse, GRMD dogs suffer 
from a rapidly progressing, fatal disease similar to DMD. There is, however, a large 
variation in disease severity as some pups survive only for a few days, while others are 
ambulant for months or even years (Ambrosio 2008). To account for this variation, it is 
possible to distinguish between the severe and the less severe pathology (Ruegg 
2009). Incomplete muscle repair in GRMD results in progressive weakness and gait 
abnormalities at the age of 6–9 weeks leading to muscle atrophy, fibrosis and 
contractures by 6 months (Ruegg 2009). The growth of affected pups is delayed and 
their walking ability is impaired. The dogs become less active than non-affected 
littermates at about 9 months of age. At this time, their gait is still uncoordinated and 
their limbs are abducted (Valentine 1988). Severely affected dogs have difficulties to 
rise and can walk only a few steps. At the age of 12 months, pharyngeal and 
esophageal dysfunctions start to develop and respiratory capacity is decreased. 
Kyphosis develops by the 6th month of age. Moreover, as seen in DMD patients, GRMD 
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dogs display selective muscle involvement although the most affected muscles in dogs 
(i.e. tongue, masticatory and trunk muscles) are different to those of humans (Kornegay 
2003). Myocardial involvement is much more evident in the golden retriever than in 
other animal models, matching very closely the cardiac complications encountered in 
DMD patients. Atrophy already appears during the neonatal period (Valentine 1988), 
although histological changes are generally not present up to 3 months of age (Moise 
1991). Systolic dysfunction and left ventricular dilation becomes apparent after several 
months or years (Moise 1991), although Tissue Doppler Imaging has allowed the 
detection of severely impaired systolic and diastolic indices in young dogs (25 ± 11 
weeks) (Chetboul 2004). Recently, NMR techniques have been applied to assess 
differences between dystrophic and healthy muscles in the dog, a method that may be 
useful to monitor a potential therapeutic response (Thibaud 2007). 
Other animal models are the HFMD cat (Gaschen 1999), the mdx 2CV-5CV mice 
(Chapman 1989), the mdx52, mdx/myoD-/-, mdx/adbn-/-, mdx/a7 integrin-/-, mdx/PV-/-, the 
Beagle (CXMDJ) (Ruegg 2009) and the Cavalier King Charles Spaniels dogs (Walmsley 
2010). 
Finally a mouse carrying the entire human DMD gene on a yeast artificial chromosome 
(YAC) was generated (hDMD mouse) („t Hoen 2008). RT-PCR, Western blot and 
immuno-histochemical analyses confirmed the expression of the human dystrophin in 
muscle, heart, kidney and testis. In the mdx mouse, the human dystrophin was able to 
rescue the dystrophic phenotype („t Hoen 2008). This system allows for the testing of 
genetic therapies affecting the human gene in a mouse background. 
 
 
9. Current therapies 
 
Pharmacological Treatment with Corticosteroids 
Glucocorticoid administration is currently the only drug treatment known to offer real 
clinical benefit to patients suffering from Duchenne muscular dystrophy (DMD). 
Glucocorticoids used to treat DMD include prednisone (Manzur 2004) and its oxazoline 
derivative, deflazacort (de Groot 2006). DMD patients treated with glucocorticoids 
exhibit delayed progression of muscle weakness (Mendell 1989) and remain ambulatory 
for a greater period of their lives (Griggs 1991). Different doses as well as different 
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intermittent schemes of administration have been tried in clinical trials with the aim of 
reducing side effects (Angelini 1994b; Merlini 2003; Biggar 2004; Connolly 2002; 
Beenakker 2005). However, there is as yet no internationally accepted consensus on 
which corticosteroid treatment scheme is the best for patients with DMD. In addition, 
there has yet to be a randomized study involving a head-to-head comparison. The 
mechanism by which patients benefit from glucocorticoid treatment is not fully 
understood, although it is thought that the clinical benefits arise in part from the anti-
inflammatory and immunosuppressive effects of these drugs (Tidball 2004). St Pierre 
and colleagues have shown that deflazacort treatment of the mdx mouse can alleviate 
symptoms of the dystrophic pathology and results in the stimulation of utrophin A 
expression in skeletal muscle fibers (St Pierre 2004) via an IRES element located at the 
utorphin 5‟UTR (Miura 2008). 
 
 
10. Potential Treatments 
 
Pharmacological Treatments 
 
Utrophin Upregulation 
The utrophin gene spans 1 Mb, giving rise to a 13 kb cDNA and a 400 kD protein 
(Pozzoli 2002). Dystrophin and utrophin show over 80% similarity in the actin-binding, 
cysteine-rich and C-terminal domains, and 35% similarity in the central rod domain 
(Pearce 1993; Tinsley 1992). Utrophin is ubiquitoussly expressed, but in adult muscle 
utrophin expression is restricted to intramuscular nerves, blood vessels and myofibers, 
where it is mainly located in acetylcholine receptor rich crests at the neuromuscular 
junctions, and at the myotendinious junctions (Khurana 1991; Nguyen 1991; Ohlendieck 
1991b). Here it recruits DGC proteins into a DGC-like complex and is probably involved 
in maintaining the structural integrity of the postsynaptic cytoskeleton (Love 1993; 
Matsumura 1992). In developing and regenerating skeletal muscle utrophin is located 
along the sarcolemma, where it is later replaced by dystrophin (Helliwell 1992; Lin 2000; 
Pons 1993). 
In DMD patients and mdx mice utrophin expression is upregulated and the protein is 
located along the entire sarcolemma, where it probably compensates to some extent for 
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the lack of dystrophin (Galvagni 2002; Karpati 1993; Khurana 1991; Mizuno 1993; 
Mizuno 1994). This theory is supported by the finding that dystrophin-utrophin double 
knockout mice have a very severe phenotype (Deconinck 1997). It is obvious that the 
upregulated levels of utrophin in mdx mice and DMD patients cannot fully compensate 
for the loss of dystrophin. However, transgenic studies with mice carrying utrophin 
overexpressing cDNA constructs have shown that a 2-3 fold increase of utrophin 
expression in the muscle could improve the phenotype of mdx mice significantly, and 
that a 10-fold increase could prevent the dystrophic phenotype entirely (Tinsley 1998). 
Thus the upregulation of utrophin gene expression is a promising approach that may be 
therapeutically applicable to DMD patients. Drugs to enhance utrophin expression in 
cultured cells and animal models have been identified by Summit PLC (John Tinsley 
and Kay Davies, UK), BioMarin Pharmaceutical Inc. and PTC Therapeutics. Clinical 
trials are under preparation. 
 
 
Myostatin inhibition 
Myostatin inhibits muscle growth. Knock-out animals for myostatin leads to increased 
muscle formation in animals (Belgium blue cattle, Texel sheep, greyhounds, mice) and 
humans. This could compensate for the loss of muscle tissue in Duchenne patients and 
can be achieved by antibodies for myostatin. Myostatin antibodies have been tested in 
healthy volunteers and were deemed safe  
(http://www.clinicaltrials.gov/ct2/show/NCT00563810?term=myo-029&rank=1). They 
were consecutively tested in adult patients with muscle diseases 
(http://www.clinicaltrials.gov/ct2/show/NCT00104078?term=myo-029&rank=2). While 
treatment was safe, it did not result in an increase in muscle mass in the patients. 
However, patients were only treated for 28 days, which might not have been long 
enough. 
 
 
Deacetylase Inhibitors 
Pharmacological interventions that increase myofiber size counter the functional decline 
of dystrophic muscles as for myostatin inhibitors (Zammit 2002). Minetti and coworkers 
showed that deacetylase inhibitors increase the size of myofibers in dystrophin-deficient 
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(mdx) and a-sarcoglycan (a-SG)–deficient mice by inducing the expression of the 
myostatin antagonist follistatin3 in satellite cells. Deacetylase inhibitor treatment 
conferred on dystrophic muscles resistance to contraction-coupled degeneration and 
alleviated both morphological and functional consequences of the primary genetic 
defect (Minetti 2006).  Colussi and colleagues elucidated the role of HDAC2 in the 
pathogenesis of Duchenne muscular dystrophy and indicate that HDAC2 inhibition by 
NO-dependent S-nitrosylation is important for the therapeutic response to NO donors in 
mdx mice for using deacetylase inhibitors in the pharmacological therapy of muscular 
dystrophies (Colussi 2008). 
 
 
Idebenone 
Buyse and coworkers tested SNT-MC17/idebenone in the mdx mouse, based on the 
drug‟s potential to improve mitochondrial respiratory chain function and reduce oxidative 
stress which is themajor cause of heart failure and death inDMD patients (Buyse 2009). 
In this study, 200 mg/kg bodyweight of either SNT-MC17/idebenone or placebo was 
given from age 4 weeks until 10 months in mdx and wild-type mice. Idebenone 
treatment significantly corrected cardiac diastolic dysfunction and prevented mortality 
from cardiac pump failure induced by dobutamine stress testing in vivo, significantly 
reduced cardiac inflammation and fibrosis, and significantly improved voluntary running 
performance in mdx mice. A Phase II extension trial where the effect of longer treatment 
was tested is now fully recruited and ongoing whilst a Phase III study has also been 
initiated and is currently recruiting patients. 
 
 
PTC-124 
PTC124 {3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid} is a chemical entity 
that selectively induces ribosomal readthrough of premature but not normal termination 
codons. Only patients with nonsense mutations would benefit from PTC124. However, 
40% of the small mutations cause a frameshift (e.g., through a one or two nucleotide 
deletion or insertion, or by interfering with normal splicing), and here PTC would not be 
applicable (Aartsma-Rus 2009a). PTC124 activity, optimized using nonsense-containing 
reporters, promoted dystrophin production in primary muscle cells from humans and 
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mdx mice expressing dystrophin nonsense alleles, and rescued striated muscle function 
in mdx mice within 2–8 weeks of drug exposure. PTC124 was well tolerated in animals 
at plasma exposures substantially in excess of those required for nonsense 
suppression. The selectivity of PTC124 for premature termination codons, its well 
characterized activity profile, oral bioavailability and pharmacological properties indicate 
that this drug may have broad clinical potential for the treatment of a large group of 
genetic disorders with limited or no therapeutic options (Welch 2007). PTC124 was safe 
in healthy volunteers. A phase II trial in Duchenne patients has been performed. 
Patients received different doses of PTC124 daily for 4 weeks. Treatment was tolerated 
well by patients and restored dystrophin clearly at highest doses. Trials to test whether 
this also results in functional improvement a longer clinical trail are currently ongoing in 
multiple centers in the USA and Europe. 
 
 
Cell Therapy 
In the last years, stem cells received much attention for their potential use in cell-based 
therapies for various human diseases. More than one clinical trial has been carried out 
with muscle stem cells in DMD patients (Mendell 1995; Torrente 2007). For several 
years after they were discovered, the satellite cell were considered as the only cells 
responsible for the growth and maintenance of skeletal muscle. With the improvements 
of cell-isolation technology, a number of markers were described to identify a lot of 
muscular and non-muscular subpopulations able to actively participate in myogenesis. 
Recent works described the partial identification and characterization of multi-lineage 
stem cells derived in culture from numerous adult tissues. Stem cell populations suitable 
for clinical experiments were found to derive from multiple region of the body at various 
stage of development such as satellite cells (Buckingham, 2006), muscle-derived stem 
cells (Qu-Petersen, 2002), side population (Asakura, 2002), bone marrow-derived stem 
cells (Dezawa et al., 2005), mesoangioblasts (Cossu, 2003), blood- (Gavina, 2006) and 
muscle-derived CD133  stem cells (Benchaouir, 2007) and pericytes (Doherty, 1998). 
Montarras and colleagues (2005) were able to directly isolate a pure population of 
satellite cells from diaphragm muscle, unfortunately it appeared clearly that the growth 
of freshly isolated satellite cells in vitro significantly reduced their in vivo myogenic 
potential and that it would be very difficult to obtain a sufficient quantity of this kind of 
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cells. This is particularly important from a clinical standpoint since cell transplantation of 
autologous genetically corrected satellite cells to DMD patients is theoretically the ideal 
approach to minimize host immune rejection of donor cells (Price, 2007). The results 
obtained in the mouse model led to test the myoblast injection in DMD patients in phase 
I clinical trials. In these trials, donor satellite cells/myoblasts were isolated from muscle 
biopsies from first-degree relatives of the affected children and were grown in culture 
(Daston, 1996; Seale, 2004). These trials demonstrated that myoblast transplantation is 
an inefficient technique; the efficiency of the dystrophin production in muscle fibres of  
DMD patients was very low ( 1%) and there was no functional or clinical improvement 
in the children (Péault, 2007). Recent studies suggested the existence of a population of 
a multipotent muscle-derived stem cell (MDSC) that resides within skeletal muscle 
sharing the ability to self renew and to differentiate into other mesodermal cell types 
(Sarig, 2006; Tamaki, 2007). Although MDSCs were amenable to therapeutic 
applications because they are easy to proliferate in vitro and able to migrate through the 
vasculature, and also multipotent (Deasy 2001 and 2005), further studies to elucidate 
the physiological location of MDSCs are required prior to the clinical use of these cells.  
In the last decade, various groups isolated and characterised the contribution of various 
nonmyogenic cells in the regeneration of skeletal muscle, such as bone marrow-derived 
cells (BMDC) and the circulating haematopoietic cells (Lennon, 2006). Adult bone 
marrow of many species contains a rare population able to extrude the vital dye 
Hoechst 33342 called Side Population (SP) (Goodell, 1997). Asakura et al., 
demonstrated that when injected into regenerating mouse mSP can differentiate into 
functional satellite cells expressing Myf5, Pax7 and desmin (Asakura, 2002). In contrast 
to satellite cells or myoblasts, mSP cells are able to migrate from the blood stream into 
muscle, a desirable feature for widespread distribution of a therapeutic cell type. 
Mesoangioblasts are multipotent progenitors of mesodermal tissues, physically 
associated with the embryonic dorsal aorta in avian and mammalian species. Early 
studies of Cossu and Bianco (2003) concerning the capacity of mesoangioblasts to 
differentiate in various mesodermal phenotypes qualified these progenitors as a novel 
class of stem cells. Cossu and coworkers transduced mesoangioblasts with a lentiviral 
vector expressing human microdystrophin and injected scid/mdx mice and dystrophic 
GRMD dogs, treated with a combination of immunosuppressive drugs and steroids 
(Sampaolesi 2006; Cossu 2007). They showed that modified mesoangioblasts 
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produced dystrophin positive myofibres in these animal models (Sampaolesi 2006; 
Cossu 2007). Nevertheless there was not a close relationship between the number of 
dystrophin-positive myofibres and the amelioration observed (Davies, 2006) and it was 
also observed that the improved muscle health determined by reduced serum kinase 
levels could be an effect of the immunosuppressive drugs and also that isolation from 
muscle blood did not exclude the presence of other muscle stem cells (Davies, 2006; 
Radley, 2006).  
Pericytes wrap around the vascular tube and interdigitate with the endothelial cells in 
the basement membrane of the vessels, playing a fundamental role in the maintenance 
of microcirculation functionality. Pericytes can be mobilized from adult bone marrow 
under ischemic conditions and utilized for their contractile capabilities and their multiple 
cytoplasmic processes. Dellavalle and coworkers demonstrated that pericytes had an 
high capacity of myogenic differentiation because they gave rise to a high number of 
muscular fibres when injected into scid/mdx mice (Dellavalle, 2007). These stem cells 
could represent a good candidate for muscle therapy because they could be isolated 
from a muscle biopsy and so easily accessible, they can be cultured in vitro without loss 
of stem-cell properties and are able to regenerate skeletal muscle after muscular and 
arterial injection (Morgan, 2007). Nevertheless, it would be important to determine,  
firstly, whether transplanted pericytes can fully reconstitute the satellite cell niche as a 
real functional stem cell (Morgan, 2007).  
CD133+ cells are considered to be haematopoietic and endothelial stem cells of bone 
marrow origin that could give rise to both endothelial cells and myoblasts (Péault, 2007). 
It has been demonstrated the stemness of circulating human CD133+ cells and their 
ability to restore dystrophin expression and eventually regenerate the satellite cells pool 
in dystrophic scid/mdx mouse after intra-muscular and intra-arterial delivery (Gavina, 
2006). Two different CD133+ subpopulations were studied: blood and muscle derived 
CD133+ cells; muscle CD133+ cells showed a better muscle regeneration in term of 
spreading and number of positive fibres in comparison with the results obtain with 
blood-derived stem cells (Benchaouir, 2007). Several things need to be ameliorated 
such as the potential to enhance proliferation of CD133+ cells in culture and storage for 
repeated treatments, the relative efficiency of blood-compared with muscle-derived cells 
to contribute muscle nuclei, a strategy to deliver myogenic cells chronically to the 
various sites of sporadic regeneration that occur in muscular dystrophies. 
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Gene Replacement 
rAAV vectors are derived from non-pathogenic and non-replicative parvoviruses 
(Athanasopoulos 2004) with a single-stranded DNA genome of approximately 4.7 kb 
(Laughlin 1983; Samulski 1982; Hermonat 1984; Srivastava 1983; Tratschin 1984) and 
a 20 nm regular icosahedral viral particle (Xie 2002). As a vector for gene transfer, all 
AAV genes (Rep and Cap) have been eliminated, with the exception of the 145 bp 
inverted Gene Therapy terminal repeats (ITRs) flanking the foreign gene(s) such as 
therapeutic or reporter genes. rAAV vector genome, lacking the Rep 78 sequence, 
primarily persists in an extrachromosomal form (Song 2004) – known as episomal 
chromatin – in the nucleus of non-dividing cells such as muscle (Penaud-Budloo 2008). 
This unique viral vector has the distinct advantage of being capable of infecting a wide 
range of host cell types including dividing and non-dividing cells (Xiao 1996; Kessler 
1996). This property makes rAAV a particularly good vector for treating diseased tissues 
such as dystrophic muscle since muscle cells do not undergo rapid cellular proliferation 
and division. The potential benefits of utilizing rAAV for the treatment of muscle 
disorders include superior long-term gene transfer efficiency, less immune response to 
the virus and a lack of toxicity in muscle, liver and heart (Manno 2003; Jung 2001; Gray 
2008), all of which are often associated with the use of other viral vectors. Two major 
disadvantages of rAAV vectors include the lack of muscle-specific gene transfer and the 
limited packaging capacity of the transgenes (< 5 kb), which affects the selective gene 
transfer capability of rAAV vector and also limits the choice of the genes of interest. 
Certain AAV serotypes demonstrate natural tropisms for muscle, making them potential 
candidates for muscle-directed gene transfer for the treatment of muscle disorders 
(Athanasopoulos 2004; Wang 2000; Gregorevic 2006; Wang 2009; Inagaki 2006). 
rAAV1 and rAAV2 are commonly applied for direct delivery and local treatment, while 
rAAV6, rAAV8 and rAAV9 are usually utilized for systemic delivery as they are the most 
efficient serotypes for crossing the blood vessel barrier to attain systemic gene transfer 
for whole-body muscle delivery, including both skeletal and cardiac muscles. rAAV 
capsid is an essential component of this vector, as it is involved in cell binding, 
internalization and trafficking within the targeted cells. To perform high-efficiency 
transduction at lower doses, rAAV capsid mutants have been developed to improve 
receptor binding and virus uptake by altering capsid plasticity (Schaffer 2004) and by 
the inclusion of a muscle-targeting peptide displayed on AAV2, which has been found to 
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improve muscle tropism during systemic delivery (Yu 2009). Of the currently used rAAV 
vectors, rAAV2 has been commonly used in human clinical trials (Rodino-Klapac 2007) 
because it has been studied extensively and is not associated with any known diseases. 
The low efficiency of rAAV2 transduction, however, limits its application to muscle gene 
delivery when compared with other serotypes. In addition, since AAV2 virus arises from 
humans, there are a considerable number of people with preexisting neutralizing 
antibodies (Chirmule 2000; Sun 2003; Wu 2006) which could affect the outcome of 
gene therapy clinical trials for the treatment of muscle diseases. More recently, there 
has been an effort to generate low-immunogenic, cell- and tissue type-specific rAAV 
vectors in an attempt to minimize human host immune response. An example of this is 
rAAV2.5, which has been used for the first gene therapy clinical trial for the treatment of 
Duchenne muscular dystrophy (DMD) (http://www. 
clinicaltrials.gov/ct2/show/NCT00428935?term=NCT00428935&rank=1). This chimeric 
viral vector was created by Dr Samulski‟s group (The University of North Carolina at  
Chapel Hill, US) through the alignment of both AAV1 and AAV2 capsid sequenze and 
resulted in 40-fold increase transduction efficiency. rAAV-based gene therapy 
represents one of the most promising approaches to aid in the treatment of DMD which 
has been demonstrated in various animal models of DMD including dystrophin deficient 
(mdx) mice (Wang 2000; Watchko 2002), dystrophin/utrophin double-knockout (dys-/-
:utro-/-) (dKO) mice (Gregorevic 2006; Wang 2009) and canine models (Wang 2007). 
However, the local treatment of skeletal and cardiac muscles for the treatment of 
muscular dystrophies is limited (Watchko 2002; Monahan 1998; Li 1999; Xiao 2000; 
Melo 2002; Yue 2003; Chu 2004; Kaspar 2005) because the muscular dystrophies 
afflict most all of the muscles of the body and the delivery of the transgene needs to be 
systemic. Intraperitoneal (i.p.) (Wang 2009) and intravenous (i.v.) (Wang 2005; Zhu 
2005) injections are often used for the treatment of experimental animal models of DMD 
and limb-girdle muscular dystrophies (LGMD); however, some serotypes of rAAV, like 
most other viral and non-viral vectors, are inefficient at penetrating the blood vessel–
tissue barrier when administered via the blood circulation. To achieve rAAV vector 
systemic delivery, both physical and pharmaceutical methods are being developed to 
surmount this barrier (Grrelish 1999; Gregorevic 2004), but all the methods currently 
under investigation are associated with severely invasive procedures and/or 
pharmaceutical side effects. Hence, for systemic gene delivery, it is important to identify 
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an appropriate rAAV serotype for skeletal and cardiac muscle transduction in order to 
efficiently deliver transgenes systemically to treat genetic diseases of muscle. Although 
AAV serotypes 6 and 8 have been commonly used for systemic delivery to skeletal and 
cardiac muscles (Gregorevic 2006; Wang 2005; Zhu 2005), a newly discovered AAV 
vector, serotype 9, has shown superior skeletal and cardiac gene transfer capacity 
(Inagaki 2006; Pacak 2006) when it is delivered via a single i.v. injection to neonatal 
normal dogs (Yue 2008) and young adult GRMD dogs (Kornegay 2009; Li 2009). The 5 
kb packaging limitation of rAAV vector limits its utility for delivery of the dystrophin gene 
(11 kb cDNA) (Wang 2000), therefore we have created a series of novel minidystrophin 
genes (< 4.2 kb) that are readily packaged into AAV vectors (Wang 2000; Wang 2009; 
Watchko 2002; Wang ET 2008). In others studies (Wang 2000; Gregorevic 2006; 
Sakamoto 2002), the rod structure and length of the mini-dystrophin protein is crucial for 
dystrophin‟s proper function, evidenced by the fact that at least one mini-dystrophin 
construct needs four rods and two hinges to have the capability to protect skeletal 
muscle fibers from the dystrophic processes. In addition to the achievements being 
made in minidystrophin replacement therapy in small and large animal models, 
important progress has been made in other areas such as exon-skipping strategies 
which is currently generating very exciting results (Aartsma-Rus 2009a; Arnett 2009; 
Goyenvalle 2004; Lu 2005; Nakamura 2009; Ruszczak 2009; Trollet 2009; van Ommen 
2008). To overcome the limitation of low potency and inefficiency of antisense 
oligonucleotide (AONs)- mediated exon skipping in systemic delivery, rAAV vectors 
have been developed to express an antisense sequence linked to a modified U7 
(Goyenvalle 2004) or U1 (Denti 2006) small nuclear RNA. As a result, exon skipping 
could remove the exons containing nonsense mutations and restore the normal reading 
frame of the dystrophin gene (Goyenvalle 2004; Denti 2008). Importantly, systemic 
delivery of AONs–AAV constructs through tail vein injections in mdx mice has resulted 
in the restoration of functional dystrophin throughout the musculature of the body and 
the improvement of muscle strength. A first clinical trial where patients received local 
AAV-microdystrophin injections in the arm muscle was performed in the USA (Mendell, 
Xiao Xiao and Samulski). Results of this trial are pending. 
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Splicing Modulation 
 
Splicing mechanism 
In most eukaryotic genes the coding sequence is dispersed over several small exons 
that are interrupted by non-coding introns. The average intron size is 3 kb, but much 
longer introns have been reported, for instance most of the introns of the DMD gene 
(Ahn 1993; Goldstrohm 2001). Introns are removed from the pre-mRNA and the exons 
joined to each other in a process called pre-mRNA splicing (see Figure 7). 
 
 
 
This process is coordinated by a catalytical complex called the spliceosome, which 
consists of 5 small nuclear ribonucleoproteins (U1, U2, U4, U5 and U6 snRNP), and 
further involves over 60 general splicing factors (Will 2001). Each snRNP contains an 
RNA part, complementary to its target sequence in the premRNA, and a protein part, to 
bind to other snRNPs or splicing factors. The initial step in the process of splicing is the 
binding of U1 snRNP to the 5' splice site. Then, the U2 snRNP is recruited to the 
branchpoint sequence by the 65 k subunit of the U2 auxiliary factor (U2AF), that binds 
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to the region of the 3' splice site. The U4-U5-U6 tri snRNP complex then replaces U1 
snRNP at the 5' splice site. When U4 snRNP detaches from the complex, U6 snRNP is 
free to bind to U2 snRNP, leading to a mature catalytically active spliceosome. The 
lariat, containing the intron and snRNPs, is then excised and the exons are joined 
together to form a mature mRNA transcript (Stojdl 1999). Correct splicing requires the 
accurate identification of the branchpoint, the 3' (acceptor) and the 5' (donor) splice 
sites of exons by the spliceosome. However, in higher organisms the consensus 
sequences for these sites is weakly defined (Zhang 1998). The only nucleotides that are 
invariably found in every intron are the GT at the start, the AG at the end and the A at 
the branchpoint (except for a small subclass of AT-AC introns (Tarn 1996) and GC-AG 
introns (Senapathy 1990)). In general 5' splice sites are determined by the sequence 
AG GTRAGt (where bold letters are invariably found, capitalized letters occur in over 
50% of analyzed splice sites and non-capitalized letters were found in over 33%, R is a 
purine (G or A) and  indicates the exon-intron boundary) (Zhang 1998). 3' Splice sites 
contain an intronic polypyrimidine stretch (pyrimidine is C or T – indicated by the symbol 
Y), which can vary in length between 2 and 32 nucleotides. The 3' splice site consensus 
sequence is (Y)2-32NCAG GN (where  is the intron-exon boundary) (Zhang 1998). The 
branchpoint is even more ambiguous: NNCTV(A)Y (where V is A, C or G and (A) is the 
branchpoint) (Zhang 1998). Online programs containing information of numerous 
human splice sites can be used to predict the likelihood that a given sequence contains 
5' or 3' splice sites (e.g. Pertea 2001: www.tigr.org/tdb/GeneSplicer/gene_spl.html ; 
Reese 1997: www.cse.ucsc.edu/~dkulp/cgi-bin/genie). Potential splice sites have a 
value between 0 and 1, where 1 is a site that matches the consensus perfectly (a strong 
splice site) and 0 denotes the absence of an identifiable potential splice site. However, 
cryptic (i.e. non genuine) splice sites with higher predicted values are present 
throughout the introns, sometimes located near weaker genuine splice sites that are 
nevertheless recognized by the spliceosome. Thus, the splicing machinery can 
distinguish between real and cryptic splice sites. This is mediated by the binding of 
spliceosomal components to genuine 3' and 5' splice sites. Many (if not all) exons 
contain exonic splicing enhancer (ESE) sequences (reviewed in (Cartegni 2002)). A 
subgroup of splicing factors, called the SR proteins, can bind to these ESEs. SR 
proteins (reviewed in (Stojdl 1999)) are localized in the nuclear speckles. They contain 
one or two RNA recognition motive sequences (RRM) and a C-terminal serine-arginine 
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stretch (RS domain), involved in protein-protein interactions with other splicing factors, 
such as the RS domain present in U1 and U2AF. Upon binding of an SR protein to an 
ESE, the SR protein recruits U1 snRNP and U2AF to their respective sites to aid 
splicing of an (weakly defined) exon. Different SR proteins have been described 
(SF2/ASF, SC35, 9G8, SRp75, SRp55, SRp40, SRp20, SRp30c, p54 and Tra2β), 
which have redundant functions. Initially discovered ESEs were invariably purine rich. 
This is probably due to the fact that these sequences can be bound by SF2/ASF and 
SC35, the most abundant SR proteins (Tacke 1995). However, recently AC-rich ESEs 
have also been described, and it appears that SR proteins are able to recognize a 
variety of sequences (Cartegni 2002; Coulter 1997). Since exons contain the coding 
sequence, which does not allow for much flexibility, the lack of a well-defined consensus 
is not surprising. It does imply, however, that it is difficult to predict which regions in an 
exon contain ESE sequences. The binding sites of SF2/ASF, SC35, SRp40 and SRp55 
have been analyzed in detail and these results are implemented in ESEfinder, which is 
a websource that predicts ESE sites (Cartegni 2003) (see below). The observation that 
a mutation in a 5' splice site often also inactivates the upstream 3' splice site and thus 
results in the skipping of the exon, led to the exon definition model (Robberson 1990): 
the exon is the first unit to be recognized during early spliceosome formation, and is 
defined by the binding of splicing factors first to the 5' and then to the 3' splice sites. 
Subsequently the intervening intron is excised. It has been shown that SR proteins can 
form a bridge across the exon to help exon definition (Achsel 1996). In addition to 
constitutive splicing, 92-94% of human genes undergo alternatively splicing (Wang ET 
2008), meaning that different splice sites or even exons are used in different transcripts 
of the same gene (see Figure 8). Exons that are alternatively spliced are characterized 
by weak splice sites and often require binding of (tissue specific) splicing factors for 
proper recognition by the spliceosome. In addition to ESEs, alternatively used spliced 
exons usually contain intronic or exonic splicing silencers. These can be bound by 
members of the heterogeneous nuclear ribonucleoprotein family (hnRNPs), which are 
the inhibitory counterparts of the SR proteins (Chen 1999). Both hnRNPs and SR 
proteins are differentially expressed during different developmental stages and in 
different tissues. The competitive binding of inhibitory and enhancer factors ultimately 
determines whether a certain splice site is used or not (Cartegni 2002). 
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Antisense-mediated restoration of normal splicing – Rational for exon skipping 
The group of Kole was first to apply AONs to modulate the splicing (Dominski 1993). 
They targeted AONs to cryptic 3' and 5' splice sites in the β-globin gene, which are 
associated with β-thalassemia. AON treatment restored normal splicing for several 
different mutations in an in vitro splicing assay. 
The observation that out-of-frame mutations in the DMD gene generally result in a 
severe phenotype, whereas in-frame mutations result in a milder phenotype prompted 
investigators to try and restore the reading frame  (Monaco 1988)(Figure 9). For 
instance, a deletion of exons 48-50 creates a frame-shift and a premature stop codon in 
exon 51, resulting in a truncated protein and DMD. A deletion of exon from 48 to 51, on 
the other hand, is in-frame, can generate an internally deleted dystrophin and is found in 
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mildly affected BMD patients (Aartsma-Rus 2009a). Thus inducing the skipping of exon 
51 in the pre-mRNA of DMD patients with an exons 48-50 deletion, would restore the 
reading frame, allow the generation of an internally truncated dystrophin and convert a 
severe DMD into a milder BMD phenotype.  
 
 
 
For most DMD patients one or more exons need to be skipped in order to restore the 
open reading frame (Tuffery-Giraud 2009; Aartsma-Rus 2009a; Flanigan 2009). Exon 
skipping can be induced by AONs targeting the splice sites, the branchpoint or exon-
internal sequences (Aartsma-Rus 2007). In each case, AON binding will hide the exon 
from the splicing machinery and consequently the targeted exon is skipped from the 
mRNA. This allows the production of internally deleted, partially functional dystrophin 
proteins, as found in BMD patients and thus has the potential to convert the severe 
DMD into a milder BMD phenotype. 
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However some exceptions to the rule do exist for example in BMD patients (out-of-
frame BMD). This is partly explained by the high incidence of 5' gene deletions in BMD 
patients (a region known to be a hotspot for exceptions), and due to complex splicing 
patterns in which a subset of transcripts show deletions larger than gDNA (exon-
skipping)(Kesari 2008). Another point to consider is that not all the in-frame dystrophin 
proteins are functional; although the dystrophin protein primarily consists of (partially) 
redundant domains, it needs its actin- and β-dystroglycan-binding domains to link the 
cytoskeleton to the extracellular matrix. Mutations affecting the domain that binds to β-
dystroglycan (exon 64-70) render the protein non functional regardless of whether 
mutations disrupt the reading frame or not (Aartsma-Rus 2006a). The link to actin is 
achieved through 3 actin-binding domains encoded by exon 2-8 (2 domains) and 35-44. 
Dystrophins lacking all three domains are non functional, while mutations where at least 
one binding is maintained generally lead to BMD, although patients lacking the first 2 
actin-binding domains often have a more severe phenotype than “typical” BMD patients 
carrying an in-frame deletion in the hotspot region (Aartsma-Rus 2006a). 
 
 
Antisense Oligonucleotides (AONs) design 
More than one study has tried to point out rules to use when designing AONs to induce 
effective exons kipping throughout the dystrophin gene (Errington 2003; Aartsma-Rus 
2005; Wilton 2007; Mitrpant 2009a; Popplewell 2009). In the first report by Errington and 
colleagues the efficiencies of exon 19 specific AONs, targeting either the 5' splice site or 
the ESE site deleted in DMD Kobe, were compared in human and mouse myotube 
cultures (Errington 2003). RT-PCR analysis revealed that both types of AONs could 
induce exon 19 skipping, but the exon internal AONs were somewhat more efficient.  
This rule could not be extended to all the exons as we learnedfrom the work by Wilton 
and co-workers (Wilton 2007). In 2005 Aartsma-Rus and colleagues retrospectively 
analyzed 114 exon-internal AONs (2‟-O-Methyl phosphorothioate modified AONs  - 
2OMePS) used to skip 36 out of 78 skippable exons identifying 4 parameters which 
were significantly different between effective and non effective AONs: effective AONs 
showed higher values of SR proteins SF2/ASF, SC35, SRp40 and a smaller absolute 
distance from 3‟ splice site (Aartsma-Rus 2005). Wilton and colleagues were able to 
skip almost all 78 exons with different efficiencies allowing a differentiation of the exons 
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in 4 groups: Types 1, 2, and 3 exons refer to exons that can be removed with high 
(greater than 30% relative to the intact transcript), medium (between 10 and 30%), and 
low (less than 10%) levels of exon-skipping efficiency, respectively. Type 4 exons 
include those from which additional flanking exons are also removed and/or more than 
one AON was required for efficient exon skipping. The only rule the authors could infer 
from this huge amount of experiments was that AONs targeting the first half of the exon 
were more effective that AONs targeting the second half of the exons (Wilton 2007). 
The same group in 2009 in an article entitled “Rational Design of Antisense Oligomers 
to Induce Dystrophin Exon Skipping” concluded: “we report substantially different levels 
of exon skipping induced in normal and dystrophic human myogenic cell lines and 
propose that animal models or artificial assay systems useful in initial studies may be of 
limited relevance in designing the most efficient compounds to induce targeted skipping 
of human dystrophin exons for therapeutic outcomes” (Mitrpant 2009a). This led to 
further studies by Popplewell and colleagues who analyzed 66 AONs (morpholinos – 
PMOs) targeting 5 exons: exons 44, 45, 46, 52 and 53. The authors concluded that 
active PMOs were longer, bind better to their target site (lower free energy compared to 
non effective AONs), target sites close to the acceptor splice site, overlapped with open 
conformations areas (as defined by hybridization or RNA secondary structure prediction 
software) and interfere with SR protein binding (Popplewell 2009). Bioinformatic tools 
helped in understanding which parameters should be considered when analyzing AONs 
(Wee 2007) although real rules are still missing. 
 
 
AON modifications 
As AON-mediated inhibition of gene expression and modulation of splicing gained more 
attention, modifications of the phosphate backbone and the sugar moiety to improve the 
biological, biochemical and biophysical characteristics of AONs were developed and 
evaluated. As a result a wide variation of different AON analogues is now available 
(reviewed in (Kurreck 2003)). The earliest modification involved the change of one of 
the non-bridged oxygen atoms in the phosphate group into a sulphate atom (De Clercq 
1969). This resulted in phosphorothioate DNA (PS), which had an increased half-time 
when compared to normal DNA. However, PS oligos induce RNase H degradation 
when bound to their RNA target, which is pivotal in sequence specific knockdown of 
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genes, but detrimental in AONmediated modulation of pre-mRNA splicing. Modifications 
at the 2'-O position of the ribose of resulted in RNA oligos that had an increased affinity 
for RNA and did not induce RNase H (Dominski 1993; Sproat 1989). The most 
frequently used 2'-O modifications are 2'-O methyl (2OMe) and 2'-O-methoxyethyl 
(2OMOE), where the 2'-O of the ribose are substituted by a methyl (CH3) group and a 
methoxyethyl (C2H4OCH3) group, respectively (Kurreck 2003). However, PS 
modifications are still required as AONs with 2'-O modifications are not very resistant to 
nucleases. Using these analogues efficient exon skipping or redirection of aberrant 
splicing can be achieved at 100 nM in human cells and at even lower concentration in 
murine cells (Aartsma-Rus 2003; Bremmer-Bout 2004; Errington 2003; Mann 2002).  
Peptide nucleic acids (PNA) are only remotely related to DNA oligos (reviewed in 
(Larsen 1999)). In PNAs the phosphate backbone is replaced by an achiral, uncharged, 
relatively flexible backbone consisting of 2-aminoethyl glycine units. The nucleobases 
are attached to these units by methylenecarbonyl linkers. PNAs are resistant to 
biological degradation by nucleases, proteinases and peptidases, and can bind to DNA 
and RNA with high affinity and specificity. The main problems with PNAs arise from their 
hydrophobic nature, which makes them insoluble and difficult to transfect (Braasch 
2002a). However, the peptide backbone is ideally suited for the attachment of carrier 
groups, to increase the cellular uptake. In addition, it has been shown feasible to 
increase the solubility and free cellular uptake to a great extent by adding 4 basic lysine 
residues to the PNA (Sazani 2001 and 2002). Yin and colleagues achieved exon 
skipping using peptide conjugated PNA AONs (Yin 2008a and 2010) although it has 
been reported that PNAs are rapidly cleared in vivo, making them less attractive as 
therapeutic compounds (Mardirossian 1997). 
Morpholinos contain a morpholino moiety instead of the ribose sugar and 
phosphoroamidate intersubunit linkages instead of phosphodiester bonds (Kurreck 
2003). They have an affinity that is comparable to DNA oligos, and are completely 
nuclease resistant and non-toxic (Summerton 1999). Due to the neutral nature of the 
morpholino backbone, undesired binding of proteins is unlikely (Summerton 1999). 
However, an unbeneficial consequence is that the cellular uptake is limited and nuclear 
uptake is even more problematic (Summerton 1999). The limited nuclear uptake is 
advantageous for translation inhibition studies, since translation takes place in the 
cytoplasm, and may explain why morpholinos have been found to be potent inhibitors of 
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protein expression in embryonic zebra fish (Nasevicius 2000). Modulation of pre-mRNA 
splicing, on the other hand, occurs in the nucleus. Low levels of exon 46 skipping were 
achieved relatively using 1000 μM of a morpholino annealed to a sense DNA leash, with 
ethoxylated PEI (EPEI) as a transfection reagent (Aartsma-Rus 2004b). Since the 
authors observed both nuclear and cytoplasmic staining of the fluorescent morpholino, 
they concluded that the low efficiency of morpholinos might be partly due to limited 
nuclear uptake. The group of Wilton has recently showed improved nuclear uptake by 
annealing the morpholino to a partially overlapping sense DNA leash, delivered as a 
cationic lipoplex (Gebski 2003). Upon entering the nucleus the leash is removed by 
nuclease degradation (starting at the non-annealed non-overlapping base pairs), freeing 
the morpholino to bind to the target sequence. Using an optimised leash, high levels of 
exon 23 could be induced in mdx myotube cultures at 300 nM, and significant levels 
were still detectable at 5 nM concentrations. 
Locked nucleic acids (LNA) are locked in the 3' endo-conformation by a methylene 
bridge that connects the 2'-O to the 4'-C of the ribose (Obika 1998). As a consequence 
LNAs are inflexible and have a very high affinity for RNA and DNA. In addition LNAs are 
non-toxic and nuclease resistant (Wahlestedt 2000). Unfortunately, the extreme high 
affinity of the LNAs may be a disadvantage rather than an advantage. LNAs longer than 
15 nucleotides will efficiently self-anneal and LNAs are not very sequence specific 
(Braasch 2002b; Fluiter 2003, Aartsma-Rus 2004b).  
Alternatively, chimeras containing a limited amount of LNA or ENA (Ethylene bridged 
nucleic acids) nucleotides have been used (Arzumanov 2001; Takeshima 2003; Yagi 
2004). For these chimeras the affinity for the target RNA is increased when compared to 
2OMePS AONs, but not so high as full-length LNAs and ENAs, meaning that they are 
more sequence specific. An RNAENA chimera targeting exon 41 of the dystrophin gene 
has successfully been used to induce exon 41 skipping in patient derived myotubes and 
dystrophin expression was observed in 80% of treated myotubes (Takeshima 2003). 
This chimera is currently being tested in a phase I/II clinical trial in Japan (Matsuo 
2004). 
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Multi exon skipping 
 
Multiexon skipping (simultaneously skipping a stretch of exons) has been proposed as a 
method to address larger groups of mutations with a similar treatment combination 
(Aartsma-Rus 2004a; Tuffery-Giraud 2009). There are a number of large deletions that 
would be suitable, since they would apply to a large group of patients and/or have been 
found in very mild BMD patients, suggesting that the resulting dystrophin is largely 
functional (Beroud 2007). Unfortunately, while multiexon skipping of a small number of 
exons is feasible (Aartsma-Rus 2004a; Fall 2006; McClorey 2006a; Yokota 2009), 
multiexon skipping of larger stretches has so far not been successful (Aartsma-Rus 
2006b; van Vliet 2008). 
 
 
Single exon skipping 
 
In vitro experiments 
Single Exon skipping could restore the open reading frame, avoiding premature 
termination codons, in 64% of all DMD causing mutations (Aartsma-Rus 2009a). AON-
mediated exon skipping feasibility in the DMD gene has been tested and achieved using 
several AON chemistries: the first attempts were performed phosphorotioate backcone 
AONs (PS AON) which can however activate RNase H. To optimize the AONs 
chemistry and sequences most of the experiments wew perdormed on mdx mouse cells 
using 2'-O-methyl modified AONs (2OMe-RNA)(Dunckley 1998; Wilton 1999; Mann 
2001), 2'-O-methyl phosphorothioate modified AONs (2OMePS) (Mann 2002; Errington 
2003; Fall 2006; Adams 2007; Mitrpant 2009a), morpholinos (PMOs) (Gebski 2003; Fall 
2006), peptide conjugated morpholinos (Moulton 2007 on mdx cardiomyocytes), PNAs 
and peptide conjugated PNAs (Yin 2008a). Several experiments were also performed 
on human myoblasts using 2OMe-RNA (Kinali 2009), 2OMePS AONs (van Deutekom 
2001; Aartsma-Rus 2002; Aartsma-Rus 2003; Errington 2003; Aartsma-Rus 2004b; van 
Deutekom 2007; Wilton 2007; Adams 2007; Mitrpant 2009a; Spitali 2009), PMOs 
(Adams 2007; Popplewell 2010; Aartsma-Rus 2004a), U7 constructs (Goyenvalle 
2007), PNAs and LNAs (Aartsma-Rus 2004b). Exon skipping has also been assessed 
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on human muscle explants (McClorey 2006b),  4cv mice derived cells (Mitrpant 2009b) 
and CKCS-MD dog derived myogenic cells (Walmsley 2010). 
 
 
 
In paper 1 we achieved single exon skipping for small mutations. Single exon skipping 
can be applied for small mutations lying within in-frame exons only, 11% of all DMD 
patients are eligible for such a treatment (Aartsma-Rus 2009a). Therefore, the general 
aim of this study was to confirm the applicability of single exon skipping to small 
mutations. We also intended to evaluate whether „„universal‟‟ or „„private,‟‟ mutation-
specific AONs were more effective in inducing the exon skipping of mutated dystrophin 
exons, effectively impacting the design of future therapies for these patients. It is, in 
fact, known that small mutations can disrupt exon splicing enhancers (ESEs) and 
silencers (ESSs), splicing regulatory sequences devoted to the exon recognition 
process (Cartegni 2003). Mutations located in ESE and ESS elements may affect 
splicing. Consequently, a significant proportion of exonic point mutations could exert an 
effect completely different as would be predicted from the genetic code. Positive and 
negative regulatory elements play opposite and fundamental roles in a finely tuned exon 
recognition process (Nielsen 2007), which need to be taken into account when 
interfering with the splicing process. Because mutations lying within ESEs may strongly 
affect the splicing process (Solis 2008), we used this double approach to point out this 
relevant topic. We have identified 54 unrelated DMD patients carrying small mutations 
in the DMD gene, of which 32 are novel. Among 24 patients carrying a mutation in an 
in-frame exon, we selected 5 mutations in 5 different exons to be modulated (exons 10, 
16, 26, 33 and 34). For the five selected dystrophin exons, the splicing specific exon 
skipping was effectively reproduced in four cell free splicing assays and in all five 
myogenic cells out of five selected mutated exons. When comparing the two different 
assays it was demonstrated that, in the absence of patient-derived cells availability, the 
cell-free assay could provide some information, but in vitro analysis in patient-derived 
cells is preferred. Furthermore, the results we obtained strongly suggest that some 
small mutations may unpredictably change the exon skipping propensity, implying that 
the exon skipping approach for in frame exons with small mutations deserves careful 
investigation. Furthermore, antisense targeting of small mutations might unravel splicing 
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regulatory motifs, because flanking introns and exons are not involved in any 
rearrangement such as deletions/duplications and every cis-regulatory motif like intronic 
splicing enhancers (ISEs) or silencers (ISSs) can play a role in the exon defining 
process. Paper 1 represents the first attempt to modulate small dystrophin mutations by 
using both wild-type and „„mutation-specific‟‟ AONs, and highlight both the peculiar  
splicing characteristics of mutated exons and the complexity of designing optimal AONs 
for exon skipping therapy toward personalized therapy. 
 
 
Restoration of the reading frame in vivo 
The first attempt in vivo was performed by Mann and colleagues (Mann 2001). Mdx 
mouse muscles (quadriceps) were injected with 1 μg of the 2‟-OMe AON together with 2 
μg of Lipofectin, once per week, either for 2 or 4 weeks. One week after the last 
injection, dystrophin was detected. Obtained dystrophin levels were rather low, 
therefore, to improve dystrophin levels, higher concentrations of AONs, new chemical 
modifications to AONs backbone (Mann 2002; Lu 2003a and 2005; Alter 2006; Vitiello 
2008; Heemskerk 2009; Yokota 2009; Wu 2010) , pepide-conjugates (Yin 2008a, 
2008b, 2009, 2010; Ivanova 2008; Jearawiriyapaisarn 2008, 2010; Wu 2008), octa-
guanidine AONs (Wu 2009), guanine analogs (Hu 2010), nano and co-polymers (Sirsi 
2005, 2008 and 2009; Williams 2006, 2008) nanoparticles (Rimessi 2009; Ferlini 2009), 
miscrobubbles (Alter 2009) and viral vectors using u1or u7 recombinant proteins 
(Goyenvalle 2004; Denti 2006; Denti 2008; Lorain 2008) have been used. 
 
 
In vivo studies 
 
AON delivery using delivery compounds 
AONs have to be present in the nucleus in order to induce antisense mediated pre-
mRNA splicing. While sufficient intra-nuclear delivery can generally be achieved in vitro 
using cationic polymers (Errington 2003), efficient AON delivery in vivo is much more 
complicated (Herweijer 2003). There are several barriers AONs have to cross in order 
to reach the nucleus, i.e. the cell membrane, the endosomal or lysosomal membrane 
and the nuclear membrane. Small DNA molecules diffuse through the nuclear pores into 
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the nucleus once they are freely present in the cytosol (Lukacs 2000). In most cases, 
however, AONs remain entrapped in endosomes and lysosomes (Loke 1989). Poly-
ethylenimine (PEI, reviewed in (Kichler 2004)), one of the most extensively investigated 
cationic polymer condenses DNA and forms DNA-PEI complexes (or AON-PEI 
complexes). By virtue of the positive charge of the PEI-DNA (or AON) complexes, they 
can efficiently bind to the anionic proteoglycans on the cell surface. This results in 
endocytosis of the complex, whereupon the pH of the endosome drops, which leads to 
the protonation of PEI and osmotic swelling of the endosome, which eventually bursts, 
releasing the DNA (or AON) in the cytosol. As mentioned before, small 
macromolecules, such as AONs can efficiently diffuse to the nucleus. There are many 
different PEIs, with different molecular weights, either linear or branched, which all have 
different characteristics (Kichler 2004). The most commonly used PEI is the linear 22 
kDa form. Transfection efficiencies of up to 100% can often be achieved in vitro using 
this PEI (Errington 2003). Unfortunately, PEI and cationic lipids are less efficient in vivo 
upon systemic delivery, probably because they interact with serum proteins, such as 
albumin, causing the dissembling of the PEI-AON complexes, resulting in exposure of 
the AON to degradation and rapid clearance (Dash 1999). Furthermore, cationic lipids 
may induce toxic effects both after systemic delivery and local injection (Kichler 2004). 
Aartsma-Rus and colleagues observed significant cytotoxicity in vitro after using high 
doses of the 22 kDA linear PEI (Aartsma-Rus 2003) and in vivo after intramuscular 
injection of AON-PEI complexes in mice, influx of monocytes and muscle degeneration 
occurred (Bremmer-Bout 2004). In the past years cationic lipids and other delivery 
systems have been modified for in vivo delivery of DNA and AONs. The most promising 
ones for delivery into muscle will be discussed here. 
The most straightforward way to deliver AONs is plainly local or systemic injection of 
pure AONs. Unfortunately, local injection is less attractive since 30% of the body 
consists of muscle. After systemic injection of PS AONs, the majority is taken up by the 
liver within 8 hours and is rapidly cleared from the body, both in rat and mice (Graham 
1998; Zhao 1998). Nevertheless, a small part of the AONs is taken up by other organs, 
including muscle (~5% of the total amount) (Akhtar 1997; Fluiter 2003). To obtain 
sufficient intramuscular concentrations, extremely high and thus toxic doses of PS 
AONs have to be injected. Increased uptake of pure DNA can be achieved by high-
pressure injection (Liang 2004; Liu 2001; Zhang 2001). DNA is injected into an artery, 
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while the draining veins are temporarily occluded (e.g. by using a tourniquet), which is 
hypothesized to temporarily disrupt the extra cellular matrix, allowing the AON to enter 
the myofibers. This appears to be efficient in mice, rats and non-human primates for 
large muscles, such as the diaphragm and the lower limb muscles (Budker 1998; Liu 
2001; Zhang 2001). However, it is unfeasible to target every muscle in the body using 
this method. Especially when one takes into account that repeated delivery is required, 
due to AON turnover. Biodistribution studies with LNA in mice revealed that the majority 
was cleared via the kidneys, and lower levels were detected in the muscle when 
compared to PS AONs (Fluiter 2003). 
A potent way to increase AONs (or DNA) delivery after intramuscular injection is  
electroporation, which induces temporary damage to the plasma membranes, allowing 
influx of macromolecules (Lu 2003b), or pretreating muscle with hyaluronidase, an 
enzyme that hydrolyses hyaluronic acid, which is the major constituent of the 
extracellular matrix surrounding the muscle fibers (Favre 2000). Wells and colleagues 
applied electroporation and hyaluronidase treatment to transfect AONs into mdx mouse 
muscle (Wells 2003). This resulted in restored dystrophin expression in 28% of treated 
myotubes as detected by immunohistochemical analysis. Dystrophin could be detected 
for at least 8 weeks. Unfortunately, electroporation is accompanied by irreversible 
muscle damage and whole body treatment is unfeasible (Aihara 1998; Bhatt 1990). 
AONs transfection efficiencies can be further improved by the application of 
microbubbles, such as Sono Vue, Sonazoid and Optison (Alter 2009). 
As mentioned before, cationic lipid-AON complexes, such as PEI are not preferred for 
systemic delivery, due to their toxicity and low efficiencies. To prevent PEI from binding 
to serum proteins or being taken up by the liver after systemic injection, PEI can be 
modified by polyethylene glycol (PEG), which shields the cationic charge (PEG-PEI 
copolymers)(Williams 2006). This reduces PEI toxicity and increases the circulation half 
time, but unfortunately also decreases PEI efficiency (Kichler 2002; Papahadjopoulos 
1991). In fact the amount of dystrophin that has been recovered by Williams and 
colleague was not enough to use the PEG-PEI copolymers for systemic delivery 
(Williams 2006). Lutz and colleagues have further investigated the possible use of PEG-
PEI copolymers by mixing 2 KDa PEI with either 550 Da or 5 KDa PEG bound to 
2OMePS resulting in a promising local delivery system (Williams 2008). 
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Alternatively, macromolar delivery systems can be applied, of which the pluronic gels 
and the nanoparticles are the most promising compounds (Hughes 2001). 
Pluronic gels consist of one or a mixture of several nonionic block copolymers. The gels 
are liquid at room temperature, but become solid at body temperature. Therefore, the 
pluronic gel acts as a depot and allows prolonged, local delivery of AONs that is over 
10-fold more efficient that pure AON injection (Lemieux 2000). The pluronic copolymer 
F127 has successfully been applied for local delivery of AONs in mdx mice (Lu 2003a). 
This resulted in the restoration of the dystrophin protein in over 20% of treated muscle 
fibers, and which could be detected for at least three months after injection. F127 is 
described as an inactive excipient and is already used for the delivery of numerous 
other drugs (von Moltke 2001). The fact that F127 becomes a solid gel at body 
temperature makes it a less suitable compound for systemic delivery. Biodegradable 
nanoparticles are small structures that either entrap AONs or bind AONs to their 
cationic surface (Hughes 2001). They protect the AONs to degradation and enhance 
transfection (Chavany 1994). However, upon degradation of the particles the extremely 
toxic formaldehyde is produced (Hughes 2001). Therefore, these nanoparcticles are not 
suitable for in vivo delivery of AONs.  
 
Two groups tested the feasibility of exon skipping in the mdx mouse using using new 
nanospheres chemistries ir order to avoid side effects: the group of Lutz (Sirsi 2009) 
and our group (Rimessi 2009; Ferlini 2010). Sirsi and co-workers have induced specific 
exon 23 skipping in the mdx mouse using biodegradable poly(lactic-co-glycolic acid) 
(PLGA) nanospheres which are made by biocompatible compounds FDA approved and 
utilized in a wide variety of drug delivery applications including the encapsulation of  
nucleic acids. Dystrophin was rescued and the number of dystrophin positive fibers was 
3.4 higher compared to naked AON injection, however these results have been 
achieved after intramuscular injestion (Sirsi 2009). 
 
 
In paper 2 we describe the first application of cationic core–shell nanoparticles made up 
of a core of polymethylmethacrylate (PMMA), surrounded by a shell bearing cationic 
groups. PMMA T1 nanoparticles have cationic groups, ideal for AONs ‟ binding, 
covalently bound to the particles thus avoiding desorption and instability problems. 
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PMMA-based nanoparticles were already described as in vivo drug-delivery systems for 
the delivery of both DNA oligonucleotides and peptides. We demonstrated that the T1 
nanoparticles can efficiently bind 2′OMePS AONs and that T1 nanoparticles are widely 
distributed in various tissues/organs including heart and skeletal muscle. We also 
showed that IP administration of the M23D AON adsorbed onto T1 nanoparticles 
induced the restoration of dystrophin protein expression in skeletal muscles and, 
although at lower levels, in the heart of mdx mice. The dystrophin rescue is associated 
with increased dystrophin transcript and expression of high molecular weight dystrophin 
protein, as shown by western blot analysis. The novel dystrophin correctly localized at 
the sarcolemma, as detected by immunohistochemical analysis. These results 
demonstrate the effectiveness of this approach both in terms of body-wide distribution 
and protein synthesis restoration. Moreover, dystrophin rescue was obtained using a 
very low dose of AON, corresponding to 1/50th to 1/80th of the routine dosage 
described in the literature for systemic treatments of mdx mice. Dystrophin synthesis is 
clearly induced by the T1/M23D complexes because the injection of the same dose of 
naked M23D did not produce any effect. The combination of slow release and depot 
effects, together with the protection from degradation/sequestration, afforded by this 
delivery system could be responsible of the very low amount of AON required for 
producing a functional effect. However a possible disadvantage in using PMMA 
nanoparticles is related to their slow biodegradability, possibly causing adverse effects 
due to accumulation in chronic treatments. 
 
 
AON delivery without delivery compounds 
Several groups have reported attempts to induce speficic exon without using any 
transfection reagent in mdx mice (Hu 2010; Wu 2010; Wu 2009; Heemskerk 2009; Yin 
2009; Hu 2010; Ivanova 2008; Vitiello 2008; Fletcher 2006 and 2007), in the mdx/utrn-/- 
mice (Goyenvalle 2010) and in the GRMD dog (Yokota 2009). 
Repeated injections of 2OMePS, PMO and PNA AONs have resulted in body wide 
dystrophin restoration, significantly improved serum creatine kinase values (a measure 
for muscle integrity) and improved muscle function in the mdx mouse model (Alter 2006; 
Fletcher 2007; Lu 2005; Yin 2010), even using repeated injections at very low doses 
(Malerba 2009). PMO treatment has also been tested in a dog model, where antisense-
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induced exon 6 and 8 skipping resulted in dystrophin restoration and improved muscle 
function (Yokota 2009). Unfortunately, for each chemistry exon skipping and dystrophin 
levels were (much) lower or non existent in heart. A breakthrough has been achieved 
with peptide conjugated PMOs (pPMOs). The addition of these arginine-rich cell 
penetrating peptides improved exon skipping levels in all muscles, and resulted in 
significant exon skipping and dystrophin restoration in heart (Jearawiriyapaisarn 2008; 
Yin 2008). A recent report showed that repeated pPMO treatment in 4 month old mice 
could ameliorate the severity of the cardiomyopathy 7 months later (Jearawiriyapaisarn 
2010). The pPMOs were also able to improve the phenotype and lifespan of the very 
severely affected double knockout mdx/utrn-/- mouse model (Goyenvalle 2010). 
However, this could only be achieved when treatment started very early (2 week old 
pups) and using relatively high doses of pPMO. Alternatively, non peptide dendrimeric 
octaguanidine moiety tags have been used to improve delivery of PMOs to skeletal 
muscle and heart (Vivo-Morpholino)(Wu 2009). Further improvement was achieved in 
mdx mice using a PMO containing both an arginine-rich peptide and a muscle-targeting 
peptide, which resulted in significant dystrophin levels in muscle and heart at very low 
doses (Yin 2009). Many different cell penetrating peptides are now under investigation 
(Ivanova 2008), and generally dystrophin restoration can be achieved with much lower 
doses than for unconjugated AONs (Yin 2009). However, these peptides have not yet 
been tested in humans. Thus, the translation into clinical trials will take more time than 
for 2OMePS and PMOs, which have already been tested in human subjects extensively.  
A disadvantage of the AON approach is that due to AON and muscle turnover, repeated 
injections are required. This could be circumvented by building the antisense sequence 
into a gene, which would allow continuous expression of the antisense sequence. The 
small nuclear ribonucleoproteins (snRNPs) provide very suitable tools for this, as they 
already consist of a RNA antisense sequence within a protein complex and are located 
primarily in the nucleus. Modification of U1 and U7 snRNPs that were delivered to 
cultured cells or to mdx mice indeed resulted in long term exon skipping and dystrophin 
restoration (over 1 year) (Denti 2006 and 2008; Goyenvalle 2004). This system also 
allows for the generation of bifunctional snRNPs that contain an antisense sequence 
and a binding motive for the hnRNP A protein, that can suppress exon inclusion 
(Goyenvalle 2009). The adenoassociated viral vector (AAV) system appears the method 
of choice to deliver these antisense genes to muscle, as it allows efficient, long term 
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transduction of muscle (Denti 2008; Goyenvalle 2004). However, some major hurdles 
need to be overcome before this approach can be tested in the clinic, e.g. the upscaling 
of medical grade AAV production, the immunogenicity problems (which precludes 
repeated injections) and the identification of ways to achieve body wide (or whole limb) 
delivery (van Ommen 2008). 
 
 
Clinical Trials 
Since exon skipping that restored the open reading frame in patients, disrupts the open 
reading frame in unaffected individuals, the exon skipping approach cannot be tested in 
healthy volunteers. Thus initial clinical trials were performed in patients using either a 
very low dose or local injections. The first trial was performed in Japan and used 4 
weekly intravenous injections of 0.5 mg/kg PS AONs (without a 2‟-O-methyl 
modification) targeting exon 19 in a single patient with a deletion of exon 20 (Takeshima 
2006). Exon 19 skipping could be detected in the patient‟s lymphocytes and at very low 
levels in patient‟s muscle. A small number of dystrophin positive muscle fibers could be 
detected in a muscle biopsy. Since exon 51 skipping applies to the largest group of 
patients, AONs targeting this exon are developed for clinical application by two 
companies. Prosensa Therapeutics (the Netherlands) and AVI Biopharma (USA). 
The hDMD mouse model has been useful for pre-clinical in vivo optimization of human 
AONs targeting exon 51 and 53 (Arechavala-Gomeza 2007; Popplewell 2010). Due to 
sequence differences between the murine and human DMD genes, human specific 
AONs generally will not result in exon skipping in mice (Bremme-Bout 2004; Heemskerk 
2009). This mouse model has been also used to confirm the efficacy of AAV delivered 
U7 snRNPs targeting human exon 51 (Goyenvalle 2010).  
Prosensa Therapeutics uses PRO051, a 2OMePS AON. Intramuscular injection of 0.8 
mg PRO051 in the tibialis anterior muscle was tested in 4 Dutch DMD patients in 2006 
(van Deutekom 2007). This was well tolerated and resulted in exon 51 skipping and 
dystrophin restoration in all patients. Similar results were obtained in 5 patients in the 
UK in a trial sponsored by AVI Biopharma (USA). These patients received an injection 
of 0.9 mg AVI-4658, a PMO, in their extensor digitorum brevis muscle, which also 
resulted in exon 51 skipping and dystrophin restoration in the absence of side ef fects 
(Kinali 2009). A lower dose (0.09 mg) of this AON was ineffective. Remarkably, the 
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number of dystrophin positive muscle fibers 64-97% vs 44-79%) and protein levels (17-
35% vs 22-32% for PRO051 and AVI-4658, respectively) were very similar for both 
trials, although differences between the two trials and methods of analysis preclude 
direct comparison (Aartsma-Rus 2009b). 
After this initial proof-of-concept in humans, current trials test systemic delivery of 
AONs. A phase I/II clinical trial sponsored by Prosensa involving 12 patients from 
Belgium and Sweden who received 5 weekly doses of 0.5 – 6 mg/kg PRO051 (3 
patients per dose) has been completed. The treatment was well tolerated for all doses. 
Preliminary results are very encouraging. Dystrophin restoration was observed for each 
patient in a dose dependent manner 
(http://prosensa.eu/news/Press%20release%20WMS.pdf). An extension study were all 
patients are treated for 6 months with the highest dose is currently ongoing in 
preparation for a phase III pivotal trial where patients will be treated for a longer time to 
allow assessment of a functional effect.  
An AVI-Biopharma-sponsored trial testing 12 weekly intravenous treatments of 0.5 – 20 
mg/kg AVI-4658 is currently ongoing in the UK. Thus far treatment is also well tolerated, 
and while no dystrophin was observed in patients treated with the lowest doses, exon 
51 skipping was observed in patients treated with 2 and 4 mg/kg and for one of the 
patients treated with 2 mg/kg dystrophin was detected as well 
(http://www.avibio.com/news_detail.php?newsId=0068). Results for the highest doses 
(10 and 20 mg/kg) are pending.  
 
 
RNA quantification studies 
The most commonly used parameter when comparing AONs is the exon skipping 
percentage. This is defined as the percentage of transcripts in which the targeted exon 
is skipped relative to the total number of dystrophin transcripts (skipped and non 
skipped). As anticipated, there appears to be a correlation between exon skipping 
percentages and dystrophin restoration in that AONs that induce high levels of exon 
skipping also lead to higher dystrophin levels than AONs that are less efficient 
(Heemskerk 2009). Thus, when optimizing AONs, assessment of exon skipping 
percentages is a relatively straightforward way to compare the efficiencies of different 
AONs. However, different ways to quantify exon skipping levels are used by different  
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groups, making it difficult to compare results between labs (Heemskerk 2009; 
Arechavala-Gomeza 2007; Yin 2008; Ivanova 2008; Lu 2005; Doran 2009; Denti 2008). 
Since dystrophin expression is rather low, cDNA synthesis followed by two rounds of  
PCR amplification (primary and nested PCRs) is the method used most, though again 
protocols greatly differ and the total number of amplification cycles can vary from ~50-
55 (Heemskerk 2009; Yin 2008; Ivanova 2008; Lu 2005) to 65-70 (Doran 2009; Denti 
2008). Only one group has recently used a single round amplification (Wu 2009 and Hu 
2010 – Qi Long Lu group) to assess exon 23 skipping in the mdx mouse. In paper 3 we 
reviewed the most used methods and compared them using AON treated mouse 
muscle derived RNA as input material in order to assess the optimal method to 
determine exon skipping percentages. We introduced as new methods to measure exon 
23 skipping in the mdx mouse model a melting curve analysis (MCA) and a digital array 
by FluidigmTM. MCA was discarded because of low sensitivity. Digital array allowed us 
to quantify the absolute exon skipping percentages and was used to compare the other 
five methods. 
Using the digital array we determined that ~1100 dystrophin transcripts are present in 1 
ng of mRNA and that 665 transcripts are sufficient to correctly determine the exon 
skipping percentage using only 30 cycles of amplification. These data match with the 
data published by Mortazavi and colleagues (Mortazavi 2008), in which an RNA-Seq 
experiment was performed in (amongst others) skeletal muscle tissue of a wild type 
mouse. When we compared different molecular approaches of several reports that 
assessed exon skipping in mdx mice we observed a huge difference in the number of 
dystrophin RNA molecules used as template ranging from 1100 to 17700 transcripts. 
We also show that all groups make use of too many amplification cycles and that the 
excessive number can lead to non reliable measurements and overestimation of  
skipping levels. We believe standardization is needed in order to better undestrand the 
outcome of different treatments inducing exon skipping. 
It has been suggested that exon skipping levels assessed by RT-PCR are 
overestimated, since the smaller skipped products are amplified more efficiently than 
the bigger nonskipped fragments. However, we show in paper 3 that for 30 
amplification cycles using a single round amplification, this is not the case. When 
comparing skipping values obtained with absolute and relative quantification via 
densitometry and bioanalyzer analysis for a single round PCR, we found that skipping 
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values were very similar. Thus, apparently stochastic effects do not interfere with the 
measurements. Most of the values that fall in a 25% error margin relative to the 
absolute quantification results, were obtained using either bioanalyzer or densitometer. 
Non-overestimation is also underlined by the finding that a one round amplification 
(20/25/30 cycles) of isolated skipped and unskipped molecules in known skipping 
percentages led to a slight underestimation of real skipping percentages rather than an 
overestimation. However, when two rounds of amplification were used, skipping levels 
were generally overestimated. Nevertheless, since dystrophin is a lowly expressed 
gene, one round of amplification might not be sufficient when analyzing exon skipping in 
cultured cells or in muscles from severely affected patients. This will require further 
investigation. We concluded that exon skipping can be quantified using different 
techniques. However, quantification using a bioanalyzer or a densitometer after primary 
amplification seems the preferred method for mdx muscle tissue derived samples, since 
the values obtained are close to the real values for both low and high exon skipping 
levels. These methods are more straightforward and significantly less expensive than 
digital array analysis, which serves as a golden standard. It is however possible that the 
optimal method(s) will differ for other exons and therefore methods to quantify the 
skipping of other (human) exons should assessed individually, although as a more 
general rule exon skipping levels should not be quantified using nested PCR. 
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ABSTRACT: Exon skipping using antisense oligonucleo-
tides (AONs) has successfully been used to reframe the
mRNA in various Duchenne muscular dystrophy
patients carrying deletions in the DMD gene. In this
study we tested the feasibility of the exon skipping
approach for patients with small mutations in in-frame
exons. We first identified 54 disease-causing point
mutations. We selected five patients with nonsense or
frameshifting mutations in exons 10, 16, 26, 33, and 34.
Wild-type and mutation specific 20OMePS AONs were
tested in cell-free splicing assays and in cultured cells
derived from the selected patients. The obtained results
confirm cell-free splicing assay as an alternative system to
test exon skipping propensity when patients’ cells are
unavailable. In myogenic cells, similar levels of exon
skipping were observed for wild-type and mutation
specific AONs for exons 16, 26, and 33, whereas for
exon 10 and exon 34 the efficacy of the AONs was
significantly different. Interestingly, in some cases skipp-
ing efficiencies for mutated exons were quite dissimilar
when compared with previous reports on the respective
wild-type exons. This behavior may be related to the
effect of the mutations on exon skipping propensity, and
highlights the complexity of identifying optimal AONs
for skipping exons with small mutations.
HumMutat 30:1527–1534, 2009. & 2009 Wiley-Liss, Inc.
KEY WORDS: exon skipping; antisense oligonucleotides;
dystrophin; DMD
Introduction
Nonsense or frame-shifting mutations in the DMD gene (MIM]
310377) lead to Duchenne muscular dystrophy (DMD; MIM]
310200), a severe X-linked neuromuscular disorder due to the
complete absence of functional dystrophin protein in males. By
contrast, the milder allelic Becker muscular dystrophy (BMD;
MIM] 310376) is caused by in-frame mutations that give rise to
a smaller but functional protein [Hoffman et al., 1987; Monaco,
1989]. The interruption or maintenance of the dystrophin reading
frame by the gene mutations explains the phenotypic differences
observed in approximately 92% of the BMD/DMD cases
[Aartsma-Rus et al., 2006; Koenig et al., 1989]. Although the
majority of the mutations in the DMD gene consists of large
rearrangements, an increasing number of both nonsense and small
frame-shifting mutations has been widely reported, due to the
improvement of the diagnostic systems [Bennett et al., 2001;
Buzin et al., 2005; Flanigan et al., 2003; Hofstra et al., 2004;
Roberts et al., 1993, 1994; Tuffery-Giraud et al., 2004; Whittock
et al., 1997]. It is now estimated that point mutations account for
nearly 30% of dystrophin mutations [Aartsma-Rus et al., 2006;
Deburgrave et al., 2007].
Due to the approach of mutation-specific clinical trials,
dystrophin mutation characterization meanwhile has become
mandatory. For instance, only patients carrying nonsense mutations
are eligible for participation in the phase I/IIa trial held by PTC
Therapeutics, based on a stop codon read-through strategy [Welch
et al., 2007]. Another mutation-specific approach is antisense-
induced exon skipping aimed at the reframing of dystrophin
transcripts. Among the various antisense types or modifications, the
20OMePS antisense oligonucleotides (AONs) targeting exon 51 have
been recently used in a pilot study in four DMD patients with very
encouraging results [van Deutekom et al., 2007].
Because the majority of DMD-causing mutations are out-of-
frame deletions clustered within the two major hotspot regions,
the exon skipping approach has been focused on this type of
rearrangements. However, it has recently been estimated that, in
theory, single and double exon skipping would be applicable
to 79% of deletions, 91% of small mutations, and 73% of
duplications, amounting to 83% of all DMD mutations [Aartsma-
Rus et al., 2009]. Indeed, only two nonsense mutations were
approached in vitro by 20OMePS AONs designed on the wild-type
exon sequence [Aartsma-Rus et al., 2003, 2004].
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Although single exon skipping for small mutations can be
applied for mutations lying within in-frame exons only, many
patients are still eligible for such a treatment (11% of all DMD
patients; Aartsma-Rus et al., 2009). Therefore, the general aim of
this study was to confirm the applicability of single exon skipping
to small mutations. We also intended to evaluate whether
‘‘universal’’ or ‘‘private,’’ mutation-specific AONs were more
effective in inducing the exon skipping of mutated dystrophin
exons, effectively impacting the design of future therapies for these
patients. It is, in fact, known that small mutations can disrupt
exon splicing enhancers (ESEs) and silencers (ESSs), splicing
regulatory sequences devoted to the exon recognition process
[Cartegni et al., 2003]. Mutations located in ESE and ESS elements
may affect splicing. Consequently, a significant proportion of
exonic point mutations could exert an effect completely different
as would be predicted from the genetic code. Positive and negative
regulatory elements play opposite and fundamental roles in a
finely tuned exon recognition process [Nielsen et al., 2007], which
need to be taken into account when interfering with the splicing
process. Because mutations lying within ESEs may strongly affect
the splicing process [Solis et al., 2008], we used this double
approach to point out this relevant topic.
We have identified 54 unrelated DMD patients carrying small
mutations in the DMD gene, of which 32 are novel. Among 24
patients carrying a mutation in an in-frame exon, we selected 5
mutations in 5 different exons to be modulated (listed in Table 1).
We induced the specific exon skipping using AONs designed either
on the wild-type or on the mutated sequence both in cell-free
splicing assays (four exons) and myogenic cell cultures (all five
exons). The predictive value of a cell-free splicing assay on exon
skipping propensity was assessed to have an alternative assay in
case cells from the patients were not available. The AONs design
was performed on the basis of well established in silico parameters
(sites for SC35 and SF2/ASF binding sites) [Aarstma-Rus et al.,
2005, 2008]. This approach follows the concept of targeting exon
sequences containing ESEs. It has, in fact, already been established
that AONs-mediated exon skipping occurs by blocking the access
of the splicing machinery to ESE sites in the exon [Aartsma-Rus
et al., 2006]. Exon-internal AONs have proven to be more effective
than AONs lying on the canonical splice sites [Aartsma-Rus et al.,
2008]. They also reduced the possible risk of off-targeting of
nonspecific sequences [Aartsma-Rus et al., 2004].
We showed that skipping efficiencies for certain mutated exons
were significantly different from what has been previously
reported for the respective wild-type exons. This is the first
report describing AONs modulation of dystrophin exons contain-
ing point mutations through efficacy comparison of the wild-type
versus the mutation-specific ‘‘private’’ AONs.
Material and Methods
Mutation Analysis
DNA from 54 unrelated DMD patients was extracted by
QIAGEN BioRobot (Universal System 8000) from whole blood,
after informed consent and for diagnostic purposes. All these
patients were negative for DMD deletions/duplications as assessed
by MLPA.
We designed a set of 79 primer pairs for single-exon amp-
lification. Oligonucleotide sequences and amplification conditions
are available upon request. The amplicons were sequenced using a
3130 automated sequencer (Applied Biosystem, Bedford, MA) Ta
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following the manufacturer’s recommendations. Supp. Table S1
lists the mutations identified. Mutation numbering system is
based on cDNA sequence (GenBank reference sequence
NM_004006.1) in which nucleotide numbering reflects cDNA
numbering with 11 corresponding to the A of the ATG translation
initiation codon in the reference sequence. The initiation codon is
codon 1.
Constructs
The five selected mutated exons and relative intron boundaries
(shown in Table 1) were amplified from the patients’ genomic
DNAs using in-house protocols (available upon request) and
cloned in the previously described pBG vector [Gualandi et al.,
2003]. Forward primers for each amplicon were designed
upstream of the branch site consensus, whereas reverse primers
were located at least 100 nucleotides downstream of the donor
splice site. The correct nucleotide composition of all constructs
was confirmed by sequencing.
AONs Design and Synthesis
Wild-type AON design was based on the highest ESE-Finder
value [Cartegni et al., 2003) (http://rulai.cshl.edu/cgi-bin/tools/
ESE3/esefinder.cgi?process5 home) and on the scores for SF2/
ASF and SC35, paying attention to the absolute distance to the
30 splice site as previously reported [Aartsma-Rus et al., 2005].
AONs sequences, characteristics, and chosen parameters are
shown in Table 1.
The AONs were synthesized with a full-length phosphorothio-
ate backbone and 20-O-methyl modified ribose molecules.
Oligonucleotide synthesis was carried out on an A¨KTATM
oligopilot plus 10 DNA/RNA synthesizer (GE Healthcare,
Piscataway, NJ) using its trityl-on mode. The sequence was
synthesized on a 2-mmol scale using Primer Support 200 loaded at
80 mmol/g (Amersham Biosciences, Piscataway, NJ) as previously
described [Rimessi et al., 2009]. The final oligonucleotide was
dissolved in water and filtered through a short column of Dowex
50WX8 (Na1 form, 100–200 mesh) to afford after lyophilization
0.8 mmol (40%) of target compound. The purity of the full-length
desired product was confirmed by MALDI-TOF MS, 31P-NMR
and RP-HPLC analyses.
In Vitro Cell-Free Splicing Assay
Five in-frame mutated exons cloned into the pBG splicing
vector, were transcribed in vitro using T7 RNA polymerase and
a32-rGTP, and purified from 5% acrylamide gel to perform in
vitro cell-free splicing assays in HeLa nuclear extracts, as
previously described [Gualandi et al., 2003]. All the splicing
products were reverse transcribed using a High-capacity cDNA
Reverse Transcription Kit (Applied Biosystems). cDNAs were
amplified using the Ex2/Ex3 oligos designed on the rabbit
b-globin sequences [Gualandi et al., 2003], cloned in the
pCRII vector (TA Cloning Invitrogen, Carlsbad, CA), and
sequenced on ABI Prism 3130 (Applied Biosystems) to confirm
the accuracy of the exon splicing process (amplification conditions
and primer sequences are available upon request).
To induce exon skipping in the cell-free in vitro system,
20OMePS AONs were used in concentrations ranging from 100 to
500 nM. The incubation lasted 3 hours. To semiquantify the
amount of the skipped transcript we performed quantification on
images from scanned autoradiographs. The fragments were
quantified by Quantity One software (BioRad, Hercules, CA).
We compared the amount of spliced products with the total
amount product in the presence as well as in the absence of AON.
We assumed that the total of the two transcripts (unspliced/
spliced) accounts for 100%.
Myogenic Cell Cultures and AONs Transfection
Primary human fibroblasts from five patients (3, 7, 18, 21, and
23 in Supp. Table S1 and listed also in Table 1) were isolated from
skin biopsies (obtained after informed consent for research
purposes, Ethical Approval N. 9/2005). Cells were cultivated in
high-glucose DMEM (GIBCO, Gaithersburg, MD), supplemented
with 20% fetal bovine serum (FBS; GIBCO) and antibiotic/
antimicotic solution (Sigma, St. Louis, MO). Myogenesis was
induced by infection with an Ad5-derived, EA1-deleted adenoviral
vector carrying the MyoD gene as previously described [Aartsma-
Rus et al., 2003; Havenga et al., 2002; Roest et al., 1996]. All
experiments were carried out using cells with a maximum of four
passages. Myotubes obtained after 10–14 days of culture in
differentiation medium (2% FBS) were transfected with AONs
(100 nM) in the presence of polyethylenimine (ExGen500, MBI
Fermentas) (2 ml per mg of AON) as transfection reagent, as
previously described [Van Deutekom et al., 2007].
Myogenic Cultures RNA Studies
Forty-eight hours posttransfection, total RNA was isolated from
myotube cultures (RNeasy Kit, Qiagen, Chatsworth, CA) and
reverse transcribed into cDNA using random primers and the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems). RT-PCR was performed on b-actin to verify cDNA
synthesis and on dystrophin (primers sequence available upon
request) using primers situated on several flanking exons to
exclude spontaneous multi-exon skipping. For exons 26 and 34 a
nested PCR was necessary to detect specific exon skipping.
PCRs were performed by five cycles of 941C (30 sec), 631C
(30 sec), and 721C (30 sec) plus 30 cycles of 941C (30 sec), 621C
(30 sec), and 721C (30 sec). PCR products were analyzed on 1.5%
agarose gels. All amplified fragments were sequenced on ABI
Prism 3130 (Applied Biosystems). We did not perform semi-
quantitative densitometric analysis on RT-PCR products, because
we adopted the Real-time quantitative assay.
Exon-Specific Real-Time Assay (ESRA)
To precisely quantify the percentage of exon skipping we set up
eight novel ESRAs detecting human dystrophin exons 6, 10, 16,
26, 33, 34, 40, and 70. These exons were chosen because they are
not involved in spontaneous alternative splicing events in humans.
We performed the ESRAs on exons 6, 10, 16, 26, 40, and 70,
considered as references, to quantify the amount of dystrophin
transcript both in patients’ and in control myotubes. In addition,
the same ESRAs were used to measure the level of physiological
exon skipping and the percentage of induced exon skipping in
treated cells compared to untreated cells (internal reference).
These data were confirmed using an external reference gene
(b-actin gene) on cDNA samples from each myotube culture
(treated and control cells). All ESRAs are based on TaqMan MGB
technology, and have been designed by PrimerExpress Applied
Biosystems software (primer and probe sequences are available
upon request). The amount of the target sequences in respect to
internal references (represented by a nonmutated dystrophin
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exon) and to an appropriate endogenous control (b-actin gene)
was evaluated by the comparative CT method in respect to the
untreated control (DDCt Method) (Applied Biosystems User
Bullettin ]2).
Immunofluorescence Analysis
Treated myotube cultures were grown onto coverslips and fixed
in 201C methanol at 2–6 days posttransfection, depending on the
survival rate of the myotubes. Samples were incubated for 30min in
phosphate-buffered saline (PBS) additioned with 4% bovine serum
albumin. All samples were labeled with a polyclonal antidystrophin
antibody (H300 Santa Cruz Biotechnology, Santa Cruz, CA) diluted
1:40, washed with PBS, and revealed with a TRITC-conjugated
antirabbit secondary antibody; all samples were double labeled with
mouse monoclonal antibodies against desmin or developmental
myosin heavy chain (Novocastra Laboratories Ltd., Newcastle upon
Tyne, UK), diluted 1:10 and 1:60, respectively. After several
washings with PBS, all samples were incubated with FITC-
conjugated antimouse secondary antibodies (Dako, Carpenteria,
CA). The slides were mounted with antifade mounting medium
(Molecular Probes, Eugene, OR) and analyzed using Nikon Eclipse
80i fluorescence microscope.
Results
Small Mutations Identification
A series of 54 patients with no deletions or duplications were
screened for small mutations. Identified mutations are reported
in Supp. Table S1. Among the 54 mutations, 32 are novel.
The mutation in patient 23 was previously described [Tuffery-
Giraud et al., 2004] and has been included in Table 1 (and Supp.
Table S1), as the fibroblasts of this patient were used for AON
modulation.
Pathogenic mutations were identified for each patient. Mutations
include splicing, frame shifting, and nonsense mutations, and 24
DMD patients show small mutations in 16 different in-frame exons.
To confirm the applicability of exon skipping for small mutations
occurring within in-frame exons we selected five patients to be
investigated (number 3 [NM_004006.1:c.1132_1135dup in exon 10],
7 [NM_004006.1:c.1912_1912delC in exon 16], 18 [NM_004006.1:c.
3447_3448delGGinsTT in exon 26], 21 [NM_004006.1:c.4565delT in
exon 33], and 23 [NM_004006.1:c.4780delTins37 in exon 34]).
AONs Design
For each exon we designed AONs specific for the mutation
(mutation specific, msAONs) and AONs not covering the
mutations (wild-type, wtAONs) (see Table 1). AONs targeting
exons 16 and 26 have been previously designed targeting the
acceptor splice sites [Wilton et al., 2007]. We decided to design
and synthesize novel exon 16 and 26 AONs targeting exon-internal
sequences. The wtAON against exon 33 is 5 nucleotides shorter
than the one reported previously [Wilton et al., 2007]. AON on
exon 34 was already designed and tested, but because it did not
produce any skipping [Wilton et al., 2007], we designed a novel
AON closer to the 30 splice site.
ESE-finder software showed that the mutations in exon 10 and
34 did not result in differences in predicted SR protein binding
sites. In contrast, the mutated exon 16 shows two additional SR
proteins binding sites caused by the mutation (among these,
the highest score was for SC35 protein). In exon 33, the mutation
causes the formation of a binding site for the SC35 protein. The
exon 26 mutation is responsible for the loss of two SR protein
binding sites.
Taking these data into account and considering that our scope
was to also include mutation-specific AONs, we were able to
design msAONs for exons 10, 16, 26, and 33 according to the rules
described above (see Materials and Methods section). The
mutation in exon 34 consists of the insertion of a novel stretch
of 37 nucleotides, and we decided to design the msAON to target
the inserted sequence. This stretch does not result in significant
changes in SR protein binding sites as predicted by ESE-finder
analysis.
In Vitro Cell-Free Splicing Assays
The five mutated exons (10, 16, 26, 33, and 34 from patients 3,
7, 18, 21, and 23 in Table 1) were cloned into the pBG splicing
vector [Gualandi et al., 2003] and analyzed using in vitro splicing
assays. Splice variants were characterized and all the exon–exon
junctions were sequenced (data not shown). In all cases the
sequencing of the cloned splicing products demonstrated that the
dystrophin mutated exons were correctly spliced between exons 2
and 3 of the rabbit b-globin gene (Fig. 1A). Antisense modulation
using 20OMePS msAONs and wtAONs was able to induce exon
skipping in four out of five constructs in cell-free splicing assays at
the scaled AONs concentration used (Fig. 1B). The semiquanti-
tative method we adopted is based on the quantification of the
amount of the spliced transcript (included exon) compared to the
total amount of product (spliced and unspliced) in the presence of
AON relative to the same ratio in the absence of AON. In a major
part of the in vitro assays the exon-skipping percentage did not
depend on the AON concentration (Fig. 1C). We therefore
calculated the average value of the skipping percentages (Fig. 1D),
which could be more easily compared to the AONs efficacy in
patient-derived cells. We observed that msAON was more efficient
for skipping exon 34 (85.55% msAON vs. 9.19% wtAON) and
exon 10 (25.63% msAON vs. 14.83% wtAON), whereas wtAON
was more efficacious for exon 33 skipping (50.72% wtAON vs.
19.93% msAON). For exon 16 we did not observe any differences
in skipping efficacy between wt and msAON (about 5%), whereas
we were not able to skip exon 26 in vitro (Fig. 1C and D).
Myogenic Cell AONs Transfection and Transcription
Analysis
The same wt- and ms-AONs tested in the in vitro splicing
system were used in cell cultures. Using both AON types we were
able to detect two products representing the unskipped and
skipped transcripts by both primary (exons 16 and 33) and nested
RT-PCR (exon 26 and 34) in patient-derived cell cultures
(Fig. 2A). In contrast, no exon 10 skipping was observed in either
primary nor nested PCR (Fig. 2A), in accordance with previously
published results obtained with the universal AON [Wilton et al.,
2007]. These experiments were highly reproducible.
RT-PCR of both untreated and treated cells did not show any
unspecific splicing product, excluding the cells carrying the exon
10 mutation, which always showed a low level of physiological
exon 9 skipping. This event has also been observed in untreated
control muscle cells [Aartsma-Rus et al., 2005; Reiss and
Rininsland, 1994].
To precisely quantify the specific level of exon skipping as well
as to detect very low skipping amounts, we used an ESRA
approach for all patient-derived treated and untreated cells. The
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quantification was made using both adjacent dystrophin exons
and b-actin as reference transcripts and in comparison to
nontreated cells. The skipping percentages are shown in Fig. 2B.
Comparing the Ct values obtained with proximal and distal
dystrophin exons (b-actin as reference), a 50-30 transcriptional
unbalance emerged, with 50 transcripts more abundant in respect
to the 30 transcripts (data not shown). We therefore quantified the
skipping percentage of the target exons using adjacent exons as
references.
In patient 3 (c.1132_1135dup in exon 10) ESRA assay using
exons 6 and 16 as references showed exon 10 skipping levels of
10.9% with msAONs, but only 2.4% of skipping with the wtAON.
In contrast, patient 23 (c.4780delTins37 in exon 34) revealed
skipping of 6.5% with wtAON and only 1.6% with msAON, using
exons 26 and 40 as references. For patients 7 (c.1912delC in exon
16), 18 (c.3447_3448delinsTT in exon 26) and 21 (c.4565delT in
exon 33) exon skipping levels were comparable for wt and ms
AONs. Exon 33 skipping levels were very high: 58.8% (wtAON)
and 58.3% (msAON) using exons 10 and 26 as references, exon 16
skipping levels were lower: 13.2% (wtAON) and 15.8% (msAON),
using exons 10 and 20 as a reference, and skipping levels for exon
26 were 1.6% (wtAON) and 2.3% (msAON), with exon 10 and 16
as reference exons. ESRA analysis, assessing the skipping level
through comparison with many references, provided robustness to
the data, allowed us to detect the exon 10 skipping not visible by
RT-PCR, and identified a low level (less than 0.5%) of spon-
taneous skipping of the mutated exons in all untreated cells.
In conclusion, the difference in skipping efficiency is significant
for exons 10 (p5 0.0002) and for exon 34 (p5 0.0017), because
msAON induced higher levels of exon 10 skipping, and wtAON
was more efficient for skipping exon 34 (Fig. 2B). In contrast, the
skipping efficiencies for exons 16 and 26 did not vary significantly.
Immunofluorescence Analysis
Immunofluorescence analysis of desmin (data not shown) and
developmental myosin heavy chain (Fig. 3A) was performed to
define the differentiation stage of the Myo-D transformed
fibroblasts. Double-labeling with antidystrophin antibodies revealed
the rescue of the protein in all patient-derived cells treated with
wtAONs or msAONs. Blinded observation as to the treatment state
was performed to quantify the cytoplasmic fluorescence counting
fluorescent cells/number of nuclei. The number of dystrophin
positive myotubes varied significantly from 5 to 15%. Lowest levels
(5%) were observed for cells with the mutation in exon 10 and
treated with the wtAON, for exon 26 treated with both wt and
msAONs, and for exon 34 treated with msAON. This corresponds
to the lower levels of exon skipping observed for these AONs
(Fig. 2B). Dystrophin localized at the sarcolemma in all transfected
myotubes (Fig. 3A and B).
Figure 1. A: In vitro cell-free splicing assay endpoint (incubation time of 3 hours), with a scheme of all possible products. Colored dots
represent the different products: black: lariat molecule; gray: unspliced template; red: splicing intermediate; yellow: exogenous exon spliced
between b-globin exons 2 and 3; green: exogenous exon skipped transcript (b-globin exons 2 and 3); blue: b-globin exon 2. B: Specific
exon skipping using 20OMePS AONs in the in vitro cell-free splicing assays. wtAONs were designed on a wild-type sequence, msAONs
were designed on mutated sequences. The five mutated exons (patients 3, 7, 18, 21, and 23) were in vitro spliced in the presence of scaled
AONs concentrations (100, 200, and 500 nM). C: Graphic representation of the densitometric analysis of the exon skipping percentages
obtained using the 100, 200, and 500 nM concentrations of all the different AONs. The colors and bars differentiate the skipping efficacy of each
mutated exon with wt or msAONs. D: Graphic representation of the skipping average value considering the results obtained using all the scaled
AONs concentration.
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Discussion
The aim of our study was to induce AON-mediated exon
skipping of in-frame exons containing small mutations. We tested
20OMePS AONs targeting both wild-type and mutated sequences
to evaluate the skipping performance and to compare the skipping
efficiency between ms and wtAONs. We took advantage from a
large cohort of patients we had identified to carry small
mutations. We modulated both in cell-free and in patient-derived
cells 5 dystrophin ‘‘in frame’’ exons (10, 16, 26, 33, and 34)
containing five different small DMD mutations.
For the five selected dystrophin exons, the splicing was
effectively reproduced in cell-free assays; however, AONs modula-
tion was successful only for exons 10, 16, 33, and 34, whereas exon
26 could not be skipped. For exons 10 and 34 msAONs worked
better, whereas for exons 16 and 33 the wtAONs produced higher
skipping levels. These data suggest that cell free splicing assays
might be used to test the exon skipping propensity. However,
because the exon composition/length as well as the flanking
intronic regions are crucial for the in vitro splicing [Eperon et al.,
1988], peculiar mutations like the long stretch included in the
mutated exon 34 could hamper the optimal AONs identification
in the in vitro assay. Therefore, it cannot be considered a general
tool for optimizing the design of the AONs.
The fact that our test produced quite different results compared
to patient-derived myogenic cells underlines this. For the mutated
exons 16 and 33, we obtained similar levels of exon skipping with
both wt and msAONs, comparable to what was previously
described for wt exons [Wilton et al., 2007].
The mutation involving exon 10, not altering the splicing
enhancer quality/distribution and therefore expected to be silent in
term of skipping propensity, makes the mutated exon vulnerable to
skipping with a 10.9% efficacy with msAON; slightly higher than
described for the wt exon in myogenic cells testing [Wilton et al.,
2007]. A possible explanation of this partially positive finding is
that the mutation changes the exon 10 conformation. Although
encouraging, the ESRA on exon 10 does not allow us to determine
whether a contextual exon 9 skipping occurs [Wilton et al., 2007].
However, we underline that exon 9 skipping is a physiological, very
common alternative splicing event, and it might therefore be very
difficult to sort out its exclusion from the transcript. In addition, as
exon 9 is in-frame, this exon skipping is unlikely to be detrimental.
Exon 26 was considered an exon difficult to skip (ratioo10%)
[Wilton et al., 2007]. In our hands, both wtAON and msAON
induced indeed a similar, very poor skipping level (1.6 and 2.3%,
respectively). This finding does not seem to reflect the expected
increase of exon 26 skipping propensity linked to the loss of the
two SR protein binding sites due to the mutation, as predicted by
the ESE finder program.
The insertion in exon 34 is difficult to analyze. Although it
appears not to have any modifying influence on splicing factors
Figure 2. A: RT-PCRs of AONs-induced exon skipping in myogenic cells. Exons 10, 26, and 34 (patients 3, 18, and 23, respectively in Table 1)
skipping was detected by nested RT-PCR, for the other two exons (30 and 33), primary RT-PCR only was performed. M is molecular weight
marker VIII, B: blank sample. B: Graphic representation of dystrophin exons 10, 16, 26, 33, and 34 skipping quantitative differences in patient-
derived AONs-treated Myo-D transformed fibroblasts in comparison with untreated cells calculated by Real-time assay (ESRA). Histograms
represent the percentage of specific exon skipping using either wtAONs (gray bars) or msAONs (white bars) of treated cells with respect to
untreated cells.
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binding sites, obviously this long stretch may alter the exon
skipping propensity in other ways. In fact, this mutation made the
exon skipping propensity in myogenic cells increase, which is in
contrast with previously published data [Wilton et al., 2007].
Indeed, we induced the skipping of the mutated exon 34 in 6.5%
of the dystrophin transcript using the wtAON in patient-derived
cells. A possible explanation is that the insertion/deletion
mutation (insertion of 37 nucleotides and deletion of 1
nucleotide) enhances the exon 34 skipping propensity by
enlarging the distance between motifs recognized by the SR
proteins and other splicing proteins. Alternatively, the RNA
secondary structure change could affect the recognition of the
mutated exon, even though the accessibility of the splice sites is
the same for wild-type and mutated exon 34 (data not shown).
In conclusion, we induced the specific exon skipping in four cell-
free assays and in all five myogenic cells out of five selected mutated
exons. When comparing the two different assays it was demon-
strated that, in the absence of patient-derived cells availability, the
cell-free assay could provide some information, but in vitro analysis
in patient-derived cells is preferred. Furthermore, the results we
obtained strongly suggest that some small mutations may
unpredictably change the exon skipping propensity, implying that
the exon skipping approach for in frame exons with small
mutations deserves careful investigation. Furthermore, antisense
targeting of small mutations might unravel splicing regulatory
motifs, because flanking introns and exons are not involved
in any rearrangement such as deletions/duplications and every
cis-regulatory motif like intronic splicing enhancers (ISEs) or
silencers (ISSs) can play a role in the exon defining process.
Notably, AON-mediated skipping of these five exons was never
accompanied by other unspecific splicing products, such as the
induction of cryptic splicing. The only alternatively spliced
product was exon 9 skipping that was also observed in control
myotubes. It is plausible (and very interesting) that fusion introns,
resulting from deletion or duplication junctions, may influence
adjacent exon recognition and therefore splicing accuracy.
Despite the promising results obtained using the exon skipping
approach, another crucial point should be considered: the possible
effect of the lack of skipped exons on the dystrophin protein.
Isolated deletions of exons 10 and 34 are described causing a BMD
or only high CK phenotype [Fokkema et al., 2005]. An isolated
deletion of exon 16 causes high CK only [Schwartz et al., 2007; and
personal observation]. For exons 26 and 33, however, no isolated
deletions are reported in the Leiden Open Variation Database
LOVD database [Fokkema et al., 2005; White and den Dunnen,
2006]. Therefore, the skipping of these exons may be of low
predictive value on the resulting phenotype(s). It might also be
possible that such deletions have not been identified yet due to the
fact that these deletions do not result in any dystrophic
phenotype. However, they all belong to the spectrin-like region
(exon 10 to the repeat 1, exon 16 to the repeat 3, exon 26 to the
repeats 7–8, exon 33 and 34 to the repeats 11 and 12), and,
according to the literature data, their skipping is expected to have
mild/BMD-like consequences on the protein function.
Figure 3. Immunofluorescence analysis of dystrophin in patients’ cells. A: Double labeling with antimyosin heavy-chain (green) and
dystrophin (red) antibodies clearly demonstrated the rescue of dystrophin expression in Myo-D tranformed fibroblasts of all treated patient-
derived cells. More than 50% of the AON-treated cells in all examined fields showed cytoplasmic green fluorescence, which was quantified as
fluorescent cells/number of nuclei. Among these, 5–15% myotubes were dystrophin positive. High magnification (B, d) demonstrates the correct
protein localization at the sarcolemma. wtAON indicates antisense oligonucleotide designed on the wild-type exon, msAON indicates antisense
oligonucleotide designed on the mutation. B: Untreated and AON treated patient’s cells stained with antimyosin heavy-chain and antidystrophin
antibodies. No dystrophin signal is detected in untreated cells (a, b), whereas dystrophin membrane signal is observed upon the induced exon
skipping in treated cells (c, d).
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The data presented here report the first attempt to modulate
small dystrophin mutations by using both wild-type and
‘‘mutation-specific’’ AONs, and highlight both the peculiar
splicing characteristics of mutated exons and the complexity of
designing optimal AONs for exon skipping therapy toward
personalized therapy.
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For subsets of Duchenne muscular dystrophy (DMD) 
mutations, antisense oligoribonucleotide (AON)-
 mediated exon skipping has proven to be efficacious 
in restoring the expression of dystrophin protein. In 
the mdx murine model systemic delivery of AON, rec-
ognizing the splice donor of dystrophin exon 23, has 
shown proof of concept. Here, we show that using cat-
ionic polymethylmethacrylate (PMMA) (marked as T1) 
nanoparticles loaded with a low dose of 2′-O-methyl-
phosphorothioate (2′OMePS) AON  delivered by weekly 
intraperitoneal (IP) injection (0.9 mg/kg/week), could 
restore dystrophin expression in body-wide striated 
muscles. Delivery of an identical dose of naked AON 
did not result in detectable dystrophin expression. 
 Transcription, western, and immunohistochemical 
analysis showed increased  levels of dystrophin tran-
script and protein, and correct localization at the sar-
colemma. This study shows that T1 nanoparticles have 
the capacity to bind and convoy AONs in body-wide 
muscle tissues and to reduce the dose required for 
dystrophin rescue. By immunofluorescence and elec-
tron microscopy studies, we highlighted the diffusion 
pathways of this compound. This nonviral approach 
may valuably improve the therapeutic usage of AONs 
in DMD as well as the delivery of RNA  molecules 
with many implications in both basic research and 
 medicine.
Received 6 August 2008; accepted 5 January 2009; advance online 
publication 24 February 2009. doi:10.1038/mt.2009.8
IntroductIon
Duchenne muscular dystrophy (DMD) is an X-linked inherited 
muscle degenerative disorder mainly caused by frame-disrupt-
ing mutations due to large rearrangements in the dystrophin 
gene.1 DMD boys are affected by both severe skeletal muscle 
wasting and dilated cardiomyopathy. The milder allelic form of 
the disease, Becker muscular dystrophy, is due to in frame muta-
tions, which preserve a shortened but functional protein. This 
 observation has suggested that converting a DMD phenotype 
to a less severe condition may represent a possible therapeutic 
approach for DMD. In this context, restoration of dystrophin syn-
thesis by exon  skipping during pre-mRNA splicing by means of 
antisense oligoribonucleotide (AON) could potentially be appli-
cable for up to 90% of DMD patients.2 Indeed, this approach has 
been successfully applied to the mdx mouse model, both in vitro 
and in vivo, to normal and DMD patients’ myogenic cells, to the 
transgenic humanized DMD mouse, and to the canine model 
of DMD. These results have therefore generated optimism about 
the feasibility of developing effective therapy approaches for 
DMD.3–5 Indeed, it was recently shown that intramuscular injec-
tion of 2′-O-methyl-phosphorothioate (2′OMePS) AONs in four 
DMD patients was associated with relevant local rescue of dys-
trophin synthesis.6 Notwithstanding these encouraging results, 
the systemic administration of AONs is limited by their cellular 
uptake and nontoxic effective doses. The main challenge in this 
field is therefore to improve the delivery of AONs to all tissues 
affected by the disease, including skeletal and cardiac muscles, 
and to reduce the effective therapeutic dose in view of life-long 
treatment.6–8 In particular, to obtain exon skipping in the heart is 
of importance, because cardiomyopathy is currently the leading 
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cause of death in DMD patients. Very recently two indepen-
dent studies described a high yield of dystrophin protein in the 
heart by systemic delivery of morpholino oligomers conjugated 
with cell-penetrating peptide containing arginine.9,10 However, 
the nondegradable nature of phosphorodiamidate morpholino 
 oligomer still raises concerns over their safety after extended sys-
temic applications.11 Experimental  evidence in the mdx model 
indicates that engineered AONs can efficiently reach the cardiac 
muscle also when cloned into recombinant adeno- associated 
virus  vectors.12 However, the intrinsic immunogenicity of virus-
associated proteins may impair the efficacy of viral-mediated 
gene inoculations  preventing  prolonged transgene expression. 
Indeed, whereas mice may be more tolerant to initial exposure 
to AAV, recent data demonstrated immune- mediated loss of 
recombinant adeno- associated virus persistence in the DMD 
dog model and in patients participating to a phase 1/2 clinical 
trial of β-hemophilia.13,14
The use of synthetic nonviral vectors based on polymeric 
 systems is a versatile and safe approach for the in vivo delivery 
of bioactive molecules, including plasmid DNA, oligonucleotides, 
and peptides. They increase their stability and shelf life in biologi-
cal fluids, improving their efficacy. Over the past decade, several 
polymeric delivery systems, such as liposomes, copolymers, nano-, 
and micro-spheres, have been developed.15 The compounds are 
encapsulated inside the polymeric matrix and released in vivo by 
a combination of diffusion and polymer degradation. However, 
 following encapsulation and release, labile drugs, such as DNA and 
proteins, may undergo significant degradation accompanied by a 
reduction in drug activity.16 Moreover intracellular drug release 
from the polymeric matrix may be too slow to be effective. In fact, 
particles could be removed from the intracellular  environment 
before much of the payload has been released.17
To achieve an effective binding, cationic micro- and nano-
spheres consisting of biodegradable polymers (poly(lactic-co- 
glycolic acid)) were therefore obtained in which cationic 
 surfactants are able to adsorb drug onto particles’ surface 
(i.e., cetyltrimethylammonium bromide) or cationic polymers 
(i.e., polyethyleneimine).18,19 However, this approach suffers from 
an inherent surface instability due to the occurrence of cationic 
surfactant desorption, thus ultimately leading to reproducibility 
problems and even toxic side effects. To overcome these prob-
lems, we designed and prepared a novel type of cationic core–shell 
nanospheres (T1), made up of a core of polymethylmethacrylate 
(PMMA), surrounded by a shell bearing cationic groups. PMMA 
T1 nanoparticles have cationic groups, ideal for AONs’ binding, 
covalently bound to the particles thus avoiding desorption and 
instability problems. PMMA-based nanoparticles were already 
described as in vivo drug-delivery systems for the delivery of both 
DNA oligonucleotides and peptides.20,21
Anionic and cationic PMMA–based nanoparticles similar 
to the T1 sample used in this study, were already shown to be 
very promising delivery systems for protein and DNA vaccines 
or for modified peptide nucleic acids as the particle/bioactive 
molecules are readily taken up by the cells where they efficiently 
release the delivered drug, are safe in mice and nonhuman pri-
mates, even after multiple administration of high doses, and 
slowly biodegradable.22–24 This knowledge prompted us to evaluate 
T1 nanoparticles as alternative vehicles to deliver charged RNA-
like AONs and to induce dystrophin rescue with improved effi-
ciency and/or with more durable effect in mdx mice. We indeed 
demonstrate that T1 nanoparticles bind 2′OMePS oligoribonucle-
otides and have a body-wide distribution following IP admin-
istration. This was accompanied with dystrophin restoration 
both in skeletal muscles and in the heart. This rescue persisted 
up to 6 weeks after the last injection. Using T1 nanoparticles, 
the effective dose of AON was highly reduced (2.7 mg/kg) when 
 compared to those used in previous studies on naked AONs deliv-
ery (120–240 mg/kg).25,26 Our results encourage further studies on 
T1 or other novel nanoparticles to evaluate applicable therapeutic 
employment for AON delivery in DMD.
results
t1 nanoparticles and Aon loading experiments
T1 nanoparticles (diameter measured by scanning electron 
micro scope 417 nm, Ζ-potential +46.5 mV, surface charge den-
sity 155 µmol/g) were obtained by emulsion polymerization 
(Figure 1a). They were made of a core of PMMA, surrounded by a 
shell bearing cationic groups. Loading experiments to test  loading 
capacity, depending on the physico-chemical properties of the T1 
nanoparticles, such as surface charge density (155 µmol/g) and 
surface area, showed that T1 nanoparticles (1 mg/ml) adsorbed 
onto their surface 2′OMePS M23D oligoribonucleotide in the 
concentration range of 10–100 µg/ml. The hydrophobic nature 
of the 2′OMePS oligoribonucleotide is responsible for its strong 
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Figure 1 t1 nanoparticles characteristics and biodistribution. (a) T1 
nanoparticle scanning electron microscope image showing the nano-
particles size (diameter 417 nm). (b) Schematic representation of the 
lipophilic interaction between antisense oligoribonucleotide (AON) 
molecules and the surface quaternary ammonium groups onto nano-
particles. (A) between two mesothelial cells of the peritoned side, and 
inside the cytoplasm of both (B) macrophages in lymphatic vessels 
and (C) endothelial cells in blood vessels (arrows). (c) Biodistribution 
of T1-Fluo nanoparticles by fluorescence  microscope analysis in group 
3 mdx mice. A, diaphragm; B, skeletal muscle (gastrocnemius); C, 
heart. Tissue sections were labeled with antinidogen antibody (red 
staining). Isolated nanoparticles are detected inside the cytoplasm or 
close to the basement membrane of the muscle fibers (arrows). Bar = 
20 μm. (d) Biodistribution of T1 nanoparticles by electron microscope 
 analysis. The diaphragm shows the presence of  several nanoparticles 
(See Supplementary Materials and Methods) EC, endothelial cell; 
M,  macrophage; MC, mesothelial cell.
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 lipophilic interaction with the surface quaternary ammonium 
groups and with the matrix of the nanoparticles (Figure 1b). 
M23D adsorption on T1 nanospheres was a highly reproducible 
process with a loading efficiency, representing the percentage of 
bound versus unbound oligonucleotides, ranging from 20 to 100%. 
In particular, the adsorption efficiency was high at low AON con-
centration and it slightly decreased at high AON concentration, 
leading to the assembling of AON/nanoparticles complexes with 
18 µg/mg of loading value (data not shown).
nanoparticles body-distribution
In order to monitor body distribution, three mdx mice (group 3 in 
Table 1) were treated via IP injections with fluorescent AON-free 
T1 nanoparticles and analyzed 1 and 6 weeks after last injection, 
obtaining similar results. Fluorescence analysis was performed on 
spleen, liver, heart, gastrocnemius, diaphragm, and quadriceps. 
In diaphragm, nanoparticles were detected close to the mesothe-
lium (Figure 1c, A). Single particles were found intracellular in 
 several myofibers of gastrocnemius and in the heart (Figure 1c, 
B and C). The number of particles/mm2 was higher in diaphragm 
when compared to gastrocnemius and quadriceps (about 10 and 
2 particles/mm2, respectively). Transmission electron microscope 
examination confirmed the presence of nanoparticles in all tissues 
examined (Figure 1d). T1 nanoparticles appeared as electron-
translucent round structures with an expected size of 500 nm. 
Nanoparticles were found both in the cytoplasm of circulating 
macrophages in lymphatic vessels and inside endothelial cells of 
blood vessels (Figure 1d, B and C).
Immunohistochemical analysis of dystrophin
In all skeletal muscles from mice treated with the T1/M23D 
complexes, dystrophin expression was restored in a significant 
number of fibers. The immunolabeling pattern was character-
ized by clusters of dystrophin-expressing fibers (Figure 2). 
Restored dystrophin localized correctly at the sarcolemma, 
and the intensity of labeling was comparable to the wild type 
(WT) muscle fibers (Figure 3a). However, in some groups of 
table 1 Mdx experiments schedule
Group  
(no. of animals)
Formulations  
dose/injections 1st Injection (day) 2nd Injection (day) 3rd Injection (day) 1st Killing (day) 2nd Killing (day)
1 (n = 6) T1/M23D 2.5 mg/45 μg 0 7 14 21 (n = 4) 60 (n = 2)
2 (n = 2) M23D 45μg 0 7 14 21 (n = 2)
3 (n = 3) T1 2.5 mg 0 7 14 21 (n = 1) 60 (n = 2)
4 (n = 6) NT NT NT NT 21 (n = 3) 60 (n = 3)
NT, not treated.
Untreated mdx
Diaphragm
Gastrocnemius
Quadriceps
C57BL6
Naked M23D 
T1/M23D treated mdx treated mdx
(1 week after 
last injection)
(1 week after 
last injection)
(6 weeks after 
last injection)
Figure 2 Immunohistochemical findings in mdx skeletal muscles. 
Dystrophin immunolabeling in muscle fibers. Representative fields of 
cross sections from C57BL6 wild type, untreated mdx, naked M23D-
treated mdx, and T1/M23D complexes treated mdx mice, diaphragm, 
gastrocnemius, and quadriceps skeletal muscle labeled with a polyclonal 
antidystrophin antibody, demonstrating absence of dystrophin in mdx 
mice untreated and treated with M23D naked AON and restoration of 
immunolabeling in several groups of muscle fibers after treatment with 
T1/M23D complexes analyzed 1 and 6 weeks after the last injection. The 
total injected amount of AON per animal, both naked or nanoparticles-
combined, was 135 μg. Bar = 40 μm.
Untreated mdx
Gastrocnemius
Quadriceps
Heart
T1/M23D treated mdx
(1 week after 
last injection)
T1/M23D treated mdx
(1 week after last injection)
(6 weeks after 
last injection)C57BL6
Untreated mdxC57BL6
a
b
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Figure 3 Immunohistochemical findings in mdx skeletal muscles and 
heart. (a) Dystrophin appears correctly expressed at the membrane of 
muscle fibers of T1/M23D-treated mdx mice both 1 and 6 weeks after 
last treatment. The intensity of labeling in rescued dystrophin-positive 
muscle fibers is reminiscent of normal muscle. No dystrophin  labeling is 
detected at the sarcolemma of untreated mdx myofibers. Bar = 20 μm. 
(b) Immunohistochemical analysis of dystrophin in heart from C57BL6, 
untreated mdx, and T1/M23D-treated mdx mice. Restoration of 
 dystrophin immunolabeling is detected in focal areas of cardiac muscle of 
mice treated with T1/M23D complexes, 1 week after last  injection. When 
compared with normal cardiac muscle, the dystrophin  immunolabeling 
appears discontinuous at the membrane of treated  cardiomyocytes. 
Bar = 50 μm.
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fibers the labeling appeared heterogeneous. We found an aver-
age of 40, 40.27, and 45% of dystrophin-expressing fibers with 
a labeling covering 90–100% of the perimeter, in  diaphragm, 
gastrocnemius, and quadriceps, respectively; the percent-
age of myofibers with a labeling ranging from 50 to 90%, was 
44.2% in diaphragm, 55.3% in gastrocnemius, and 45.5% in 
quadriceps. Moreover, 10% in diaphragm, 3% in gastrocne-
mius, and 4% in quadriceps of  myofibers showed a discontinu-
ous pattern or a labeling that covered <50% of the perimeter. 
Immunohistochemical analysis of dystrophin in cardiac mus-
cle of all T1/M23D-treated mdx mice examined 1 week after 
last injection revealed the presence of groups of dystrophin-
expressing cardiomyocytes in different areas of the heart 
(Figure 3b). Dystrophin was absent in the heart of T1/M23D-
treated mice killed 6 weeks after last injection (data not shown) 
and in control mdx mice (Figure 3b).
Quantitative analysis of dystrophin-positive fibers was performed 
in skeletal muscle of mdx mice treated with T1/M23D complexes, 
while cardiac muscle was not evaluated; the count of dystrophin-
positive fibers in skeletal muscle excluded myofibers with a labeling 
that covered <50% of the perimeter or with a discontinuous pat-
tern. The average of positive-muscle fibers varied between different 
skeletal muscles (Figure 4a). The number of dystrophin-positive 
fibers found in mdx mice treated with T1/M23D complexes was 
significantly increased when compared to mdx mice treated with 
the same dose of naked M23D or to control mdx mice, untreated or 
treated with T1-Fluo AON-free nanoparticles. mdx mice examined 
1 week after last injection showed the highest number of dystro-
phin-positive fibers in diaphragm and quadriceps and the lowest in 
gastrocnemius. In mdx mice examined 6 weeks after the last injec-
tion, the highest  number of dystrophin-positive fibers was detected 
in gastrocnemius and the lowest in diaphragm and quadriceps.
Western blot
By western blot analysis the expression of dystrophin was clearly 
detected in gastrocnemius, quadriceps, and diaphragm from all 
mdx mice groups treated with T1/M23D complexes, examined 
both 1 and 6 weeks after last injection, but undetectable in the 
heart as well as in mdx mice treated with naked M23D or untreated 
(Figure 4b). Two different antibodies against dystrophin produced 
similar results. The size of the protein was indistinguishable from 
the full-length dystrophin of the normal muscle, as expected for a 
protein translated by a single exon 23 skipped transcript. No other 
lower molecular weight products were seen.
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mdx T1 (group 3)
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Figure 4 Positive fibers counting and western blotting. (a) The 
 statistical analysis shows a significant increase of dystrophin-positive 
fibers in diaphragm, quadriceps and gastrocnemius of mdx mice treated 
with T1/M23D complexes (group 1) if compared to mdx mice treated 
with M23D naked AON (group 2) or with T1 nanoparticles (group 3; see 
Table 1). The average of dystrophin-positive myofibers varies among 
different skeletal muscles and the mice examined 1 and 6 weeks after 
the last injection. Data represent mean ± SD. §P < 0.05. *P > 0.05. 
(b) Dystrophin immunoblot using DYS2 antibody shows restored expres-
sion of the protein in diaphragm, gastrocnemius, and quadriceps muscle 
from T1/M23D complexes treated mdx (lanes 3 and 4: 1 week after last 
injection, lane 5: 6 weeks after last injection, group 1 in Table 1), while 
no protein is detected in mdx untreated control (lane 2). Dystrophin 
protein is undetectable in heart from both untreated and treated mdx 
mice. Diaphragm, gastrocnemius, quadriceps, and heart from normal 
mice are used as positive controls, 1/30th of protein loaded in the 
other lanes (lane 1). AON, antisense oligoribonucleotide; T1,  cationic 
polymethylmethacrylate.
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Dystrophin transcript quantitative analysis
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Figure 5 transcript and exon skipping quantification. (a) Quanti-
fication of dystrophin transcript in skeletal and cardiac muscles from mdx 
treated and untreated animals in respect to wild type mice  (considered 
as 100%). Dystrophin transcript expression was evaluated by relative-
quantitative Real-Time PCR using β-actin as endogenous control. 
Histograms represent dystrophin transcript level calculated by the mean 
of exons 7, 22 and 25, 2−ΔΔCT values (expressed as percentage) in differ-
ent skeletal muscles (diaphragm, quadriceps, and gastrocnemius) and 
heart. A total of 26 experiments has been performed (column represents 
the mean values). The analysis was performed on mdx mice from three 
different groups killed 1 week after the last injection: group 1 (n = 4; grey 
column), group 2 (n = 2; white column), and group 4 (n = 6; black col-
umn). (b) Percentage of exon 23 skipping determined by Real-time PCR 
in cardiac and skeletal muscles from mdx treated animals in compari-
son with untreated mice. The analysis was performed on group 1 mice 
(n = 4) in respect to group 4 mice (n = 3), all killed 1 week after the last 
injection. The percentage of exon 23 skipped transcript (2−ΔΔCT  values) 
calibrated on exon 7, was evaluated in three different  experiments and 
appeared to be clearly assessable in the cardiac muscle (16%; grey 
 column) as well as in the skeletal muscles, represented by gastrocnemius 
and quadriceps (6%; white column).
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transcription studies
Quantitative evaluation of T1/M23D treatment on general 
 dystrophin transcriptional level. In order to quantify differences 
in the amount of dystrophin transcript both in skeletal and  cardiac 
muscle from untreated, T1/M23D- and naked M23D-treated 
 animals, we performed a quantitative analysis using exon specific 
real-time assays (ESRAs). This demonstrated that untreated mdx 
mice showed a generally lower transcription level in respect to the 
amount of the transcript (considered as 100%) detected in the WT 
mice, therefore used as control. In addition, the transcription  level 
in mdx follows a muscle-specific pattern, being the higher level of 
messenger in diaphragm (34% of the WT) and heart (14%), where-
as lower levels were seen in gastrocnemius (10%) and quadriceps 
(6%) (Figure 5a). The mdx mice group 1 (Table 1), treated with 
T1/M23D compound and killed 1 week after last injection, showed 
a significant increase of dystrophin transcription levels in the heart 
(80% more transcript), gastrocnemius, and quadriceps (70% and 
50% more, respectively), although at different  extent among treat-
ed mice (Figure 5a). No effect was observed in the diaphragm, 
where transcription level remained comparable in treated and un-
treated animals. The mdx mice group 2, treated with naked M23D, 
did not show significant difference in the  dystrophin transcription 
level in comparison with untreated mdx mice (Figure 5a).
Exon 23 skipped transcript quantification. The percentage of 
exon 23 skipped transcript, calibrated to exon 7 and taking as 
 endogenous control mouse β-actin gene, appeared to be clearly 
assessable in the cardiac muscle (16%) as well as in the skeletal 
muscles (6%) of T1/M23D-treated mdx mice analyzed 1 week after 
last injection (Figure 5b). In addition, the correct exon 22–exon 
24 junction was assessed by sequencing the nested PCR product 
(See Figure S2). Quantitative analyses were also  performed on the 
treated mdx mice killed 6 weeks after last  injection; however, the 
transcription levels were comparable to those of untreated mdx 
mice, and the exon 23 skipped transcript was undetectable.
dIscussIon
In this work, we describe the first application of cationic core–
shell nanoparticles as effective nonviral vehicles for the  delivery of 
charged AONs in vivo. We demonstrated that the T1  nanoparticles 
can efficiently bind 2′OMePS RNA-like  oligonucleotides. We also 
demonstrated that T1 nanoparticles are widely distributed in 
 various tissues/organs including heart and skeletal muscle. We 
also showed that IP administration of the M23D AON adsorbed 
onto T1 nanoparticles induced the restoration of dystrophin pro-
tein expression in skeletal muscles and, although at lower levels, 
in the heart of mdx mice. The dystrophin rescue is associated with 
increased dystrophin transcript and  expression of high  molecular 
weight dystrophin protein, as shown by  western blot analysis. The 
novel dystrophin correctly localized at the sarcolemma, as detected 
by immunohistochemical  analysis. These results  demonstrate 
the effectiveness of this approach both in terms of body-wide 
 distribution and protein synthesis restoration.
Moreover, dystrophin rescue was obtained using a very low 
dose of AON, corresponding to 1/50th to 1/80th of the  routine 
dosage described in the literature for systemic treatments of mdx 
mice.25,26 Dystrophin synthesis is clearly induced by the T1/M23D 
complexes because the injection of the same dose of naked M23D 
did not produce any effect. The combination of slow release and 
depot effects, together with the protection from  degradation/
sequestration, afforded by this delivery system could be  responsible 
of the very low amount of AON required for producing a func-
tional effect. The above suggestion is supported by the well-known 
hydrophobic nature of phosphorothioates,27 which is responsible 
for the strong lipophilic interactions of  oligonucleotides with 
 quaternary ammonium groups and matrix of the nanoparticles.
Because a moderate toxicity is documented for PS-AONs, 
even in view of chronic treatment, the possibility of obtaining 
 sustainable effects by using a very low dose is certainly realistic.
The second interesting result is the dystrophin rescue obtained 
in the heart, as shown in treated mdx mice killed 1 week after the 
last injection. Although we are aware that the amount of dys-
trophin rescue in the heart is low, we should consider that it has 
been obtained by 1/80th of the dose previously administered for 
systemic delivery of 2′OMePS.25 It is also known that other AON 
molecules as phosphorodiamidate morpholino oligomer-AONs do 
not reach the heart spontaneously but only when conjugated with 
cell-penetrating peptides.9,10,26 Therefore, despite the low amount 
of rescue as well as the lack of its persistence after 6 weeks, the T1/
M23D complex represents the first conjugate able to improve the 
2′OMePS oligomer uptake by systemic administration.
Although delivery of 2′OMePS was demonstrated to be 
improved by using synthetic cationic copolymers of polyethyl-
eneimine and poly(ethylene glycol), this delivery was performed 
only locally because systemic administration of these copolymers 
may present toxic effects.3,28–30
We have also set up a novel quantitative analysis (ESRA) 
of dystrophin transcripts that provided the identification of a 
 muscle-specific pattern of transcription in untreated mdx mice 
in comparison with WT mice. We used both β-actin and adja-
cent dystrophin exons as reference transcribed regions. The ESRA 
analysis allowed us both to identify a wide increase of transcrip-
tion levels after treatment in the different muscles, including heart, 
and to quantify the dystrophin exon 23 skipped transcript in the 
heart (16%) and in skeletal muscles (6%). The increased amount 
of dystrophin transcript in T1/M23D-treated mdx mice could be 
due to an enhanced stability of skipped transcript and/or to the 
inhibition of nonsense mediated decay. The difference between 
heart and skeletal muscle exon 23 skipped transcript amounts is 
remarkable. Furthermore, it is also evident that there is a discrep-
ancy between transcript and protein rescue, being inversely pro-
portional in heart versus skeletal muscle. Although explaining this 
peculiar but relevant finding requires further studies, there are 
data showing that both the transcription and translation  behavior 
varies between heart and skeletal muscle. This may be due to 
cis/trans acting tissue specific factors able to destabilize or stabilize 
the transcripts or more generally to the different  transcription and 
translation efficiency in both tissues.31,32
Histological analysis showed no apparent tissue damage in 
any of the organs examined, such as liver, kidney, and spleen 
(Figure S1).
A possible disadvantage in using PMMA nanoparticles is 
related to their slow biodegradability, possibly causing adverse 
effects due to accumulation in chronic treatments. Furthermore, 
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T1 nanoparticles might not be appropriate for intravenous usage, 
because the possibility to form small aggregates, expected by 
using >2.5 mg of nanoparticles.24 For these reasons and in order to 
improve the potential for such a novel approach, we are  currently 
testing different nanoparticles, varying in size, RNA binding 
 affinity, and bioerosion propensities.
In summary, our results show that IP administration of a low 
dose of specific AON–nanoparticle complexes can effectively 
restore dystrophin synthesis in both skeletal and cardiac muscle. 
Nanoparticles are therefore eligible as candidate delivery systems 
for RNA molecules supporting further investigations in particu-
lar for DMD AON-mediated therapeutics.
MAterIAls And Methods
AON synthesis. M23D(+07-18) (5′-GGCCAAACCUCGGCUUACCUG
AAAU-3′) AON against the boundary sequences of the exon and intron 
23 of mouse dystrophin gene, contains 2′-O-methyl modified RNA and 
full-length phosphorothioate backbone.33 Oligonucleotide synthesis 
was carried out on an ÄKTA oligopilot plus 10 DNA/RNA synthesizer 
(GE Healthcare, Milano, Italy) using its trityl-on mode. The sequence 
was synthesized on a 2-μmol scale using Primer Support 200 loaded at 80 
μmol/g (Amersham Biosciences, Milano, Italy). Commercial 2′-O-methyl 
phosphoroamidites (Proligo, Boulder, CO) were dissolved to a nominal 
concentration of 50 mmol/l in anhydrous acetonitrile (CH3CN) and acti-
vated with a 0.25 mol/l solution of 5-(bis-3,5-trifluoromethylphenyl)-
1H-tetrazole (Proligo) in CH3CN. The final detritylation was achieved 
using a 0.1 mol/l aqueous solution of NaOAc (pH 3.0). Crude dimeth-
yltryptamine protected and detritylated oligonucleotide were purified 
by an ÄKTAbasic ultra physical contact liquid chromatography system 
using an Amersham Biosciences Resource RPC 3 ml column eluted under 
a gradient of CH3CN in 0.1 mol/l  triethylammonium acetate (pH 8).
The final oligonucleotide was dissolved in water and filtered through 
a short column of Dowex 50WX8 (Na+ form, 100–200 mesh) to obtain 
after lyophilization 0.8 μmol (40%) of target compound. The purity of the 
full-length desired product was evaluated by MALDI-TOF MS, 31P-NMR 
and RP-HPLC analyses.
T1 nanoparticles loading experiments. For phosphorothioate modified 
RNA-like oligonucleotide (2′OMePS-AON) adsorption experiments, 
1.0 mg of freeze-dried nanospheres were suspended in 1.0 ml of 20 mmol/l 
sodium phosphate buffer (pH 7.4) and sonicated for 15 minutes. The 
appropriate amount of a concentrated aqueous solution of 2′OMePS-
AON was then added to reach the final concentration (10 ÷ 100 µg/ml). 
The experiments were run in triplicate (SD ≤ 10%). The suspensions were 
continuously stirred at 25 °C for 2 hours. After microfuge centrifugation 
at about 18,000 rpm for 15 minutes, quantitative sedimentation of the 
AON–nanoparticle complexes was obtained and aliquots (10 ÷ 50 µl) of the 
supernatant were withdrawn, filtered on a Millex GV4 filter unit and diluted 
with sodium phosphate buffer. Finally, UV absorbance at λ = 260 nm was 
measured. Adsorption efficiency (%) is calculated as 100 × (administered 
AON) − (unbound AON)/(administered AON).
Animals. All experiments were performed on male mdx mice (C57BL/ 
10ScSn–Dmdmdx/J) or age-matched WT male mice (C57BL/10SnJ). 
All procedures were approved by the Animal Experimentation Ethics 
Committee. Mice were housed in temperature-controlled rooms (22 °C) 
with a humidity of 50% and a 12:12 hour light–dark cycle. Mice were 
 purchased from the Jackson Laboratory (Bar Harbor, ME).
IP injections of T1–AON complexes, T1-Fluo-AON free, and naked 
AON. T1 nanoparticles toxicity tests were performed both in mice 
and in murine/human cells using up to 5 mg/injection (IP) in animals 
and 10 mg/ml in cells. No toxicity was observed both in in vivo and in 
in vitro systems (A. Caputo, Department of Histology, Microbiology, and 
Medical Biotechnology, personal communication, September 2006).
mdx mice (8–10 weeks of age) were IP injected with 250 μl of T1/M23D 
complex, containing 45 μg of M23D AON and 2.5 mg of T1 nanoparticles 
(thought to represent a well-tolerated dose both for multiple IP and 
for IV administration) dissolved in sterile unpreserved saline solution 
(0.9% sodium chloride), or 250 μl containing 45 μg of M23D dissolved 
in unpreserved saline solution, and monitored according to approved 
NIH and University guidelines. The complex suspension (250 μl) was 
slowly injected through the abdominal skin into the peritoneal cavity 
using an insulin syringe fitted with a 28-gauge needle. One group of mdx 
mice (n = 6) (group 1) received three identical injections of T1/M23D 
complex at days 0, 7, and 14. One group of mdx mice (n = 2) (group 2) 
received three identical injections of M23D naked AON at the same times. 
Controls were age-matched mdx mice injected at days 0, 7, and 14 with 
fluorescent T1 AON-free nanoparticles (n = 3) (group 3) and untreated 
mdx mice (n = 6) (group 4) as negative controls. The total amount of 
the administered M23D AON was 135 μg/animal. Table 1 summarizes 
treatments and killing of mice analyzed in the present work.
Harvest of tissues. At 1 week after the third injection, four mdx mice of group 
1, two mdx mice of group 2, one mdx mouse of group 3 and three mdx mice 
of group 4, were killed and diaphragm, gastrocnemius, quadriceps, and car-
diac muscles were isolated, blotted dry, trimmed of external tendon, pinned 
to Parafilm-covered cork, snap frozen in liquid N2-cooled isopentane, and 
stored at −80 °C until further processing. Muscles from the two remaining 
mdx mice of group 1 together with the control mdx mice, two from group 
3 and three from group 4, were harvested 6 weeks after the last injection 
(16–18 weeks of age). Liver, kidney, and spleen were also harvested.
Fluorescent microscope analysis of nanoparticles distribution. Seven-
micrometer thick frozen sections of liver, spleen, heart, diaphragm, quad-
riceps, and gastrocnemius skeletal muscles from mdx mice of group 3 
(Table 1) were labeled with a rabbit antinidogen antibody (Calbiochem, 
San Diego, CA), selected as marker of basal lamina, incubated with an 
antirabbit tetramethyl rhodamine iso-thiocyanate–conjugated  secondary 
antibody (DAKO, Glostrup, Denmark), washed several times with phos-
phate-buffered saline and observed with a Nikon Eclipse 80i fluorescence 
microscope (Nikon Instruments, Firenze, Italy). Serial  sections, obtained 
from three different levels of each organ at 100-μm intervals were observed 
at 100× and images recorded with a Nikon digital camera.
Transmission electron microscope study of nanoparticles  distribution. 
Liver, spleen, kidney, diaphragm, gastrocnemius and quadriceps  skeletal 
muscles, and heart were fixed with 2.5% glutaraldehyde in 0.1 mol/l 
phosphate buffer for 3 hours and with 1% osmium tetroxide in Veronal 
buffer for 2 hours, dehydrated with ethanol and embedded in Epon 
E812.
Ultrathin sections were stained with lead citrate and uranyl acetate 
and observed in a Philips EM 400 transmission electron microscope (FEI, 
Hillsboro, OR), operated at 100 kV.
Immunohistochemical analysis of dystrophin. Seven-micrometer thick 
frozen sections of heart, diaphragm, quadriceps, and gastrocnemius skel-
etal muscle fragments from mdx treated with M23D AON T1-conjugated 
 complex (group 1), M23D naked AON (group 2), T1-Fluo AON-free 
(group 3), and untreated mdx mice (group 4), were labeled with a  polyclonal 
 antidystrophin antibody (Santa Cruz Biotechnology, Santa Cruz, CA) 
diluted 1:100, incubated with an antirabbit tetramethyl rhodamine iso-
 thiocyanate–conjugated secondary antibody (DAKO), washed several 
times and observed with a Nikon Eclipse 80i fluorescence microscope.
Evaluation and quantification of dystrophin-positive fibers. Dystrophin 
immunolabeled transverse sections from WT, treated, and untreated mdx 
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mice were analyzed with a Nikon Eclipse 80i fluorescence microscope at 
20× and images were taken with a fixed exposure time (0.5 seconds) using 
an high-resolution CCD camera (Nikon). Images were analyzed by NIS-
Element BR2.20 (Nikon) imaging program and the threshold intensity for 
each tissue was determined on sections of WT mice. Because in T1/MD23 
treated mdx mice groups of fibers showed a heterogeneous pattern, the per-
centage of the perimeter truly labeled by the antibody was determined for 
each fiber by using the AnalySIS program (Soft Imaging System, Muenster, 
Germany). The count of dystrophin-positive fibers excluded myofibers 
with a labeling that covered <50% of the perimeter or with a discontinuous 
pattern. The number of dystrophin-positive fibers was evaluated on three 
different levels, 300 μm apart from each other, in the diaphragm, gastroc-
nemius, quadriceps, and on eight serial sections, at 100-μm intervals, of the 
heart. At least 3,000 muscle fibers from the diaphragm and gastrocnemius 
and 5,000 from the quadriceps muscles, respectively, obtained from three 
different levels of tissue blocks for each sample, were studied for statistical 
evaluation; data were analyzed according to Mann–Whitney test, and the 
criterion for statistical significance was P < 0.05.
The counts were performed blind to sample identity and the relative 
patterns were confirmed by an independent observer in order to unbias 
the observation.
Sodium dodecyl sulphate–polyacrylamide gel electrophoresis and immu-
noblotting analysis. Twenty-micrometer thick frozen muscle sections 
were homogenized with a lysis buffer containing 7 mol/l urea, 2 mol/l thio-
urea, 1% amidosulfobetaine-14, and 0.3% dithioerythritol, and then cen-
trifuged at 1,500g for 10 minutes. Protein concentration was determined 
in the supernatants with the Bradford method. Aliquots of proteins from 
normal C57BL/10 mice (10 µg) and from muscles of treated or untreated 
mdx mice (300 µg) were loaded onto a 6% T sodium doedecyl sulphate–
polyacrylamide gel and separated by electrophoresis. Samples were trans-
ferred to a nitrocellulose membrane overnight at 75 V. The membrane was 
blocked with nonfat dried milk for 60 minutes at room temperature and 
incubated overnight at 4 °C with the specific antibody DYS2 (a mouse 
monoclonal antibody to the carboxy terminal region of dystrophin, 1:100, 
NovoCastra, Newcastle, UK) or H-300 (a rabbit polyclonal antibody to 
the internal region of dystrophin, 1:200, Santa Cruz Biotechnology). After 
intervening washes, the membrane was incubated with horseradish per-
oxidase–conjugated goat antimouse or antirabbit IgG diluted 1:40,000 or 
1:30,000, respectively. Immunocomplexes were visualized with the ECL 
Advance Western Blotting Detection Kit (Amersham Pharmacia Biotech, 
Buckinghamshire, UK).
RNA studies. Total RNA was purified from muscle biopsies of WT 
(n = 2), untreated (n = 6), and treated mdx mice (n = 8), by using RNeasy 
kit (Qiagen, La Jolla, CA) and reverse transcribed into cDNA using 
the high capacity cDNA reverse transcription kit (Applied Biosystems, 
Frankfurt, Germany). Six novel ESRAs detecting mdx exons 7, 8, 22, 23, 
25, and 56, were specifically developed for this study. These exons were 
chosen because they do not undergo spontaneous alternative splicing. 
ESRA on exons 7, 22, 23, and 25 were used to quantify the percentage of 
exon 23 skipping in treated mice. Dystrophin transcript quantification 
was performed by comparison with the β-actin gene on each isolated 
muscle from both treated and control mdx mice. All these ESRAs are 
based on TaqMan technology and have been designed by PrimerExpress 
Applied Biosystems software (Applied Biosystems). Primers and probes 
sequences are available upon request. The amount of target sequences in 
respect to appropriate endogenous control (β-actin gene) was evaluated 
by the comparative CT method with respect to the endogenous β-actin 
control (ΔΔCt Method) (Applied Biosystems User Bulletin no. 2). Nested 
RT-PCR was performed as described in ref. 25, skipped transcript was 
analyzed by sequencing (ABI PRISM 3130 Automated Sequencer; 
Applied Biosystems).
suPPleMentAry MAterIAl
Figure S1. Morphological analysis of liver, kidney, and spleen from 
mdx mice treated with T1/M23D complex.
Figure S2. Nested RT-PCR analysis of dystrophin mRNA in muscle 
 tissues of wild type, untreated, and T1/M23D-treated mdx mice.
Materials and Methods.
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